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Abstract 
Controlled-release tablets enhance the effectiveness of therapies for various clinical 
conditions. Photocrosslinkable polyanhydrides that undergo surface erosion were recently 
introduced as suitable materials for manufacturing tablets with tunable release profiles. 
However, their erosion behavior has not been comprehensively studied. In this thesis, the 
erosion kinetics of photocrosslinkable polyanhydrides was studied by exploring the impact of 
different parameters (the polymer composition and geometry, as well as the temperature, pH, 
and shaking rate of the solution during the in vitro experiments) on their mass loss profiles, 
followed by a release kinetic model fitting. The results indicate that the temperature was the 
only parameter that could affect the induction period (the lag time) substantially. Moreover, 
polymers with the same surface area to volume ratios showed similar mass loss percentage 
despite their dissimilar volumes and surface areas. Although tablets with adjustable release 
profiles have been studied before, lack of a fast and large-scale production technique is a 
significant limitation that holds back their widespread application. A high-throughput 
fabrication platform was developed that was then utilized to manufacture controlled-release 
polyanhydride tablets. Tunable release profiles with the high-throughput fabricated tablets 
were achieved. 
Keywords 
Controlled-release drug delivery system, surface erosion, polyanhydrides, erosion kinetic, 
drug-loaded tablets, adjustable release profiles, high-throughput fabrication. 
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Summary for Lay Audience 
Oral drug delivery is the preferred route for medication administration due to its lower cost 
and higher convenience for patients compared to other methods such as injection and 
implantation. The conventional form of oral tablets, however, requires multiple 
administrations to maintain the concentration of drugs in the bloodstream at an effective 
level. Controlled-release tablets have emerged as an alternative that can sustain the drug 
dosage at an effective level for a long period of time, aiming at enhancing the effectiveness 
of therapies in various clinical conditions. In addition, tablets with adjustable release profiles 
of the drug have been explored to improve the treatment efficacy for diseases that require 
different temporal profiles of the drug concentration. These tablets are typically made of a 
special class of polymers called biodegradable polymers, meaning that they are safely 
decomposed by the human body after they release the drug. 
Polyanhydride is a biodegradable polymer that is considered as an appropriate option for 
being used in the fabrication of tablets with adjustable release profiles. Polyanhydrides are 
mostly eroded from their surfaces at predictable rates when they are exposed to the aqueous 
media. Understanding the erosion behavior (and hence the mass loss profile) of a newly 
introduced type of polyanhydride is an essential step before its utilization in fabricating 
tablets with adjustable release profiles. In this thesis, we first studied the erosion behavior of 
the new type of polyanhydride by exploring the impact of different parameters on their mass 
loss profiles. Moreover, we fitted the experimental mass loss data to different release kinetic 
models to gain a better understanding of the erosion behavior.  
Although tablets with adjustable release profiles have been around for a while, lack of a fast 
and large-scale production technique has remained an important limitation that holds back 
their widespread application. We developed a high-throughput fabrication platform that we 
then utilized to manufacture polyanhydride tablets with controllable release profiles. We 
achieved tunable release profiles with the high-throughput fabricated tablets. Finally, we 
increased the capacity of the tablets for drug loading by implementing and fabricating 
modified tablet designs. 
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Chapter 1  
1 Introduction 
This chapter provides an overall introduction to the thesis work. 
1.1 Overview  
Oral drug delivery systems (DDSs) comprise more than 50% of the drug delivery market. 
Patients prefer the oral route for drug administration because it is economical, 
noninvasive, and does not require expertise for administration1,2. Conventional means of 
oral DDSs release the entire therapeutic substance immediately after administration. This 
leads to an instant increase, followed by a rapid decrease (to a sub-therapeutic level) in 
the drug concentration in the bloodstream. Therefore, to keep the drug concentration at 
therapeutic levels, multiple administrations at regular intervals are required. 
Controlled release systems (CRSs) have emerged to enhance the patients' compliance and 
convenience by improving drugs’ efficacy, reducing the chances of drug toxicity, and 
eliminating the need for multiple administrations3. Biodegradables polymers have been 
widely used in controlled DDSs because of their tunable mechanical properties. Synthetic 
biodegradable polymers, in particular, are of interest due to their unlimited availability4.  
A biodegradable polymer undergoes mass loss either by bulk erosion or by surface 
erosion. Most of the biodegradable polymers used in CRSs, e.g. polyesters, undergo bulk 
erosion. Bulk-erodible polymers erode from their interior and exterior simultaneously, 
resulting in low predictability of the drug release kinetics from these polymers. In 
contrast, surface-erodible polymers lose the polymer moieties from their surface, and 
therefore their initial geometry is preserved while the size of the polymer decreases. 
Besides, the mechanical properties of the surface-erodible polymers do not change during 
the erosion. The highly reproducible and predictable release kinetics of the surface 
eroding polymers make them desirable options in manufacturing the controlled DDSs3.  
Polyanhydrides predominantly undergo surface erosion because of their hydrophobic 
backbone and hydrolytically unstable anhydride bonds. Polyanhydrides have been shown 
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to maintain their surface eroding behavior at sizes as small as 100 𝜇m, that is the smallest 
value reported for surface eroding polymers5. Unlike other surface-erodible polymers 
such as polyorthoesters (POEs) that undergo surface erosion only in acidic environments, 
polyanhydrides have shown surface erosion in acidic, alkaline, and neutral 
environments6. Despite their attractive properties for controlled DDSs7, polyanhydrides 
have not been used as often compared to other biodegradable polymers such as 
polyesters. This can be attributed to the difficulties involved in their synthesis. In 2009, a 
new photocrosslinkable polyanhydride using thiol-ene polymerization was reporeted8. 
The polymerization process was straightforward and fast compared to other processes 
used for polyanhydrides synthesis.  
Fully characterization of the new type of polyanhydrides, as well as investigating the 
impact of different parameters on its erosion behavior are essential before its utilization 
in controlled DDSs. There exist some parameters that may substantially affect the erosion 
of thiol-ene polyanhydrides, but have not yet been studied. For example, the polymer 
composition, temperature, pH of the media, the geometry of the polymers, and the media 
shaking rate (the convective force for the polymer erosion). The first objective of this 
study is to explore the erosion behavior of this type of polyanhydrides and gain a better 
understanding of their mass loss profiles. We then use these polymers for fabricating 
tablets with a new design proposed in this study (see below). 
Controlling the temporal profile of drug release is vital for achieving the optimal 
therapeutic effect. Despite the substantial progress in developing controlled-release 
tablets, most of the existing designs only offer monotonic, or sustained release profiles. 
However, different types of clinical circumstances necessitate different types of release 
profiles for optimal treatment. The temporal patterns are mostly defined by the effect of 
the circadian rhythm on different clinical circumstances, giving rise to specific rhythms 
of medical conditions during the 24 hours of the day. Besides, various factors such as the 
patient’s condition, age, and gender call for patient-specific treatments via personalized 
medicine. The increased awareness of individualized therapy and introduction of various 
biodegradable polymers with adjustable physicochemical properties encourage the 
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development of fabrication methods for manufacturing advanced controlled DDSs that 
enable releasing of drugs at controllable rates. 
The traditional compression tableting that is used by pharmaceutical industries for 
manufacturing tablets and capsules9 does not provide the flexibility required for 
fabricating controlled DDSs. Micro-fabrication has been used in some studies owing to 
its ability to manufacture tiny features while providing control over the shape or 
geometry of the delivery devices. The combination of micro-fabrication techniques such 
as standard photolithography, with repeated replica molding steps, has been reported that 
allows for easy, rapid, and precise manufacturing of drug delivery devices at relatively 
low costs10,11. This method has been used to fabricate microchips as CRSs that generate 
long-term pulsatile release12. Although the micro-fabrication methods provide a high 
resolution and have the potential for high-throughput manufacturing, the limitations 
associated with using implantable microchips have left the oral controlled DDSs the 
preferred option13,1. 3D printing is another technology that has been studied extensively 
by researchers for fabricating polymeric oral tablets with adjustable release profiles14. 
Most of the studies fabricated tablets with monotonic or constant release profiles of 
drugs, with some reporting more complicated (e.g. pulsatile) release profiles. The 
complicated release patterns were achieved by elaborate tablet designs and specific 
fabrication techniques, demonstrating the feasibility of creating tablets with various 
release patterns of drugs. 
Although these studies show that the fabrication of personalized tablets is no longer an 
issue, there exist some limitations in the current fabrication methods used for modified-
release tablets that can hinder their widespread application. Some of these limitations can 
be addressed by improving the tablet design and/or the appropriate choice of the 
fabrication method. As an example for the latter, the resolution of the fabrication method 
is an important parameter that can determine the precision of the release rate. The 
inexpensive and commercially available 3D printers have relatively low resolution, while 
higher resolution 3D printers are limited by their small range of resins (printable 
materials). On the other hand, micro-fabrication techniques such as photolithography are 
capable of creating miniaturized features with high resolution. Besides resolution, 
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scalability and high-throughput manufacturing is a critical characteristic of any 
potentially successful fabrication method. High-throughput manufacturing is currently a 
challenge for producing advanced controlled DDSs with adjustable release rates. Most of 
the studies reported the fabrication of a single tablet in each experiment, reducing the 
chances of their practical use in clinical settings. Manufacturing each tablet can take 
considerable amount of time, and the reproducibility level is low.        
The second objective of this study is to use the thiol-ene polyanhydrides that we 
characterized during the first step for high-throughput fabrication of tablets with the new 
design proposed in this thesis. We aim at addressing the challenges in the fabrication of 
controlled-release tablets with adjustable release profiles of drugs by developing a high-
throughput fabrication platform that manufactures tablets with high resolutions. 
1.2 Thesis Outline 
This thesis is divided into five chapters. A brief introduction and the motivation for this 
research are included in Chapter 1. 
The relevant background information on the role of biodegradable polymers in controlled 
DDSs, the importance of polyanhydrides as surface eroding polymers, parameters 
affecting the erosion of polyanhydrides, the need for different release profiles of drugs, 
and the key concepts of advanced fabrication methods for manufacturing CRSs with 
adjustable release profiles is provided in Chapter 2. A broad literature review on the 
current research and challenges of obtaining erosion kinetics of thiol-ene polyanhydrides 
is also presented in Chapter 2. Lastly, the advances in controlled DDS fabrication 
methods are discussed focusing on micro-technology and 3D printing methods. 
The main research findings are presented in chapters 3 and 4. Chapter 3 reports a 
comprehensive study on the mass loss profile of thiol-ene polyanhydrides. This chapter 
details the materials used in the mass loss experiments followed by the methodology of 
polymer preparation and characterization, experimental designs to explore the effect of 
different parameters on mass loss of the thiol-ene polyanhydrides, and the theoretical 
concepts for release kinetic model fitting. The results of the effects of parameters on mass 
5 
 
loss (erosion) profiles of polyanhydrides synthesized by thiol-ene photopolymerization 
are discussed. A comparative study on the release kinetic models and their fitting to the 
experimental data is carried out for a better understanding of polymers’ erosion behavior. 
Chapter 4 reports the high-throughput fabrication of tablets that are designed using a new 
approach, enabling adjustable drug release rates. The methodology of developing a high-
throughput platform using a combination of micro-fabrication and 3D printing 
technology for rapid manufacturing of the erodible tablets is provided in this chapter. 
Several experiments were conducted with various tablet designs, and the results show the 
different release profiles obtained from these tablets. 
Chapter 5 summarizes and concludes the results of chapters 3 and 4 and provides 
directions for future work. 
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Chapter 2  
2 Background and Literature Review 
This chapter provides the relevant background information on the emergence of 
controlled release technology, the role of biodegradable polymers in controlled release 
DDSs, and highlights the importance of polyanhydrides, as surface eroding polymers, in 
achieving desired release rates required in personalized medicine. Parameters affecting 
the erosion behavior of polyanhydrides and studies on these parameters is discussed. 
Lastly, this chapter discusses recent developments in fabrication methods of polymeric 
DDSs with controllable release profiles of drugs; focusing on using micro-technology 
and 3D printing for oral dosage forms. 
2.1 Polymeric Controlled Drug Delivery Systems 
This section describes the conventional DDSs and discusses the need for CRSs. 
2.1.1 Conventional Drug Delivery Systems 
The oral dosage is the most common route for the delivery of therapeutic agents, 
constituting about 40% of the drug administrations1. When administered orally, 
therapeutics are safely taken by patients without the assistance of a healthcare 
professional. In comparison to injection administration routes (e.g., subcutaneous, 
intramuscular, intravenous), oral delivery has minimal discomfort. These advantages of 
oral drug delivery over other drug administration routes, as well as the ease of the drug 
administration and the high level of patients’ convenience, have resulted in the allocation 
of more than 50% of the drug delivery market to oral DDSs2,3. 
Conventional means of oral DDSs release therapeutic substances all at once (immediate-
release) resulting in a sudden increase of drug concentration followed by a rapid decrease 
to a lower than effective level of drug in the bloodstream. In such settings, the duration in 
which the plasma concentration is effective without being tioxic is short, rendering the 
conventional release systems suboptimal. Figure 2-1 shows the importance of keeping the 
drug concentration level in the therapeutic window (below the toxic and above the sub-
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therapeutic level). This figure also displays multiple administrations required for drugs to 
maintain their concentration within the therapeutic window. The multiple administrations 
reduce the patients’ compliance and cause fluctuations in the drug dose level in the blood. 
 
Figure 2-1: Drug plasma concentration in conventional DDSs that requires multiple drug 
administrations to keep the concentration of the drug in the therapeutic window. 
2.1.2 Emergence of Controlled Release Technology 
Controlled DDSs have emerged to improve patients’ health by improving the drug 
efficacy, reducing the dose-dependent drug toxicity, and enhancing patient compliance 
and convenience. The tunable release of therapeutic substances in response to time or 
different stimuli (temperature, pH, enzymes, etc.), while maintaining the dose at the 
effective level, is called controlled release drug delivery4. Maintaining the level of the 
biologically active agents in the effective zone decreases the chances of drug toxicity, and 
hence the side effects. Controlled DDSs are designed to sustain the required plasma 
dosage for an extended period of time and consequently eliminate the need for frequent 
administrations. Figure 2-2 compares the burst release of a drug through the conventional 
means of delivery with drug release from a controlled DDS. Figure 2-2 also shows an 
example of a pulsatile release as an example of a physiologically required release profile 
that can be achieved by designing more complicated controlled DDSs5. 
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Controlled DDSs often utilize synthetic biodegradable polymers to act as carriers for 
delivering their cargos. Several biodegradables polymers have been widely used to create 
the controlled DDSs. Based on the site of action and the desired temporal release profile, 
polymers with specific physicochemical properties can be utilized6. 
 
Figure 2-2: Comparison of the conventional DDSs’ burst release with sustained-release 
obtained by a controlled DDS. The pulsatile release is one of the critical physiologically required 
release pattern, which is achievable using controlled DDSs. Reproduced from Ref 5 with 
permission. 
2.1.2.1 Biodegradable Polymers in Controlled DDSs 
Biodegradable polymers have been widely used in drug delivery applications because of 
their advantages over other materials, specifically their adjustable mechanical properties 
as an important factor for achieving more efficient DDSs. In the past 50 years, synthetic 
biodegradable polymers have been preferred over the naturally occurring ones for the use 
in advanced delivery systems due to their availability and their easily adjustable 
physicochemical properties7. In the 1960s, polyesters such as poly(D,L-lactic acid) 
(PLA), poly(glycolic acid) (PGA), and their copolymer poly(D,L-lactic-co-glycolic acid) 
(PLGA) were developed as synthetic biodegradable polymeric sutures8. Since then, 
synthetic biodegradable polymers have been extensively used as biocompatible delivery 
systems that are easily eliminated after the therapeutic is released in the human body. 
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Aliphatic polyesters such as PLA, PGA, and polycaprolactone (PCL), among 
biodegradable polymers, are the most frequently used materials in biomedical 
applications owing to their availability, biocompatibility, and flexible degradability9. 
These polyesters, as well as other synthetic biodegradable polymers, including 
polyphosphazenes, polyurethanes, polyanhydrides, and POEs, have been extensively 
studied over the past 20 years for advanced DDSs applications9–11. 
2.1.3 Controlled Drug Release Mechanisms 
A variety of available drugs in the market for the treatment of different diseases increases 
the importance of using CRSs to elevate the efficacy of those drugs. The primary role of 
CRSs is releasing drugs for an extended period (days to weeks) at a controllable rate. A 
significant number of CRSs have been developed for various clinical conditions. 
Choosing the most suitable delivery system required for a specific clinical condition 
requires knowledge about different mechanisms of CRSs as well as their systems design  
factors4.  
CRSs utilizing polymers as carriers are divided into five main categories: diffusion and 
dissolution, solvent activated (swelling and osmotic-controlled), ion-exchange, stimuli-
responsive, and chemically mediated (erosion and degradation controlled) systems4,12. 
These categories and the mechanisms by which they control the drug release will be 
briefly discussed in this chapter with the focus being on the chemically-controlled 
mechanisms, which are employed in this study. 
2.1.3.1 Diffusion and Dissolution CRSs 
Diffusion release is the most common mechanism of releasing drugs from polymers12. 
The migration of compounds from their initial point to the lower concentration area in the 
polymer is called a diffusion release mechanism. Diffusion CRSs are designed as 
reservoir systems or polymeric matrix systems. Reservoir systems typically consist of a 
water-insoluble polymeric membrane through which the drug diffuses out while in 
polymeric matrix systems, the drug is released by passing through the matrix itself. 
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As shown in Figure 2-3A, in both reservoir systems and polymeric matrices the drug can 
be dissolved in aqueous solution either above the saturation concentrations (constant drug 
source reservoir and monolithic dispersion matrices) or below the saturation level (non-
constant drug source reservoir and monolithic solution matrices). In the former case, the 
concentration of the drug inside the polymer decreases over time by releasing the 
dissolved drug. Therefore, undissolved drug aggregates will be dissolved in order to 
replace the released drug, which leads to a controlled release rate (almost zero-order 
release). When the drug aggregates have fully dissolved, the concentration of the drug in 
the polymer goes under the saturation level. From this step onward, the constant drug 
source reservoir and monolithic dispersion matrices behave similarly to non-constant 
drug source reservoir and monolithic solution matrices, respectively, where the amount of 
the drug-releasing out of the polymer decreases over time until the completion of the drug 
release4, as shown in Figure 2-3A. 
Dissolution CRSs can also be designed as reservoirs or matrix systems (Figure 2-3B). 
Slowly dissolving polymers coat drugs in reservoir systems and the dissolution rate of the 
polymer defines the release rate of drugs. In dissolution-controlled matrix systems, drugs 
are encapsulated within a polymer and are released while the matrix is dissolving. 
Therefore, one of the essential factors for selecting the suitable polymer for a dissolution 
CRS is the solubility of the polymer that affects the release rate of the loaded drug13. 
Most of CRSs are a combination of the diffusion and dissolution systems in which drugs 
are trapped in polymeric membranes or matrices. Due to polymer dissolution, some pores 
will be created that allow water penetration to the polymer. As a result of the water flow 
inside the polymeric structure, the drug diffuses out of the polymeric matrices or 
membranes. Sometimes one of these mechanisms dominates the other that results in 
dissolution-limited or diffusion-limited CRSs14. 
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Figure 2-3: Schematic illustration of A) Diffusion CRSs. Drugs are trapped in systems at time t0 
and diffuse out through the reservoir systems or polymeric matrices at time t1 and t2. In non-
constant drug source reservoirs or monolithic solution systems, the concentration of the drug 
reduces over time while the drug release can be controlled for a prolonged time in constant drug 
source reservoir or monolithic dispersion systems. B) Dissolution CRSs. In reservoir systems, the 
thickness of the membrane determines the drug release rate by controlling the dissolution rate of 
the polymer. In matrix systems, the dissolution of the boundary layer determines the release rate 
of the drug. Reproduced from Ref 4 with permission. 
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2.1.3.2 Solvent-activated CRSs 
The penetration of water or body fluids into some polymeric systems causes the 
controlled release of drugs. Solvent-activated systems can be divided into swelling-
controlled and osmotic pressure-controlled systems12. 
Semipermeable polymeric membranes which are permeable to water and impermeable to 
drugs produce osmotic pressure in osmotic pressure-controlled systems. There are small 
holes (orifices) on these membranes, acting as pathways for drugs to be released. Figure 
2-4A shows two types of osmotic CRSs: 1) the drugs are loaded in the osmotic core (type 
A) or 2) the drugs are trapped in the reservoir surrounded by the osmotic core (type B). 
The osmotic pressure caused by the water permeation into the polymeric membrane 
through the orifices is the driving force of the drug release. Permeability of the polymeric 
membrane, the size of orifices, and the level of osmotic pressure control the release of the 
biologically activated agents4,14,15.    
In swelling-controlled systems, polymers such as natural or synthetic hydrogels are used 
that can absorb a considerable amount of water after being immersed in water. When 
these polymers swell in the presence of water or body fluids, their volume increases and 
the contents of the solvent come out from the polymer (Figure 2-4B). Diffusion of the 
drug through the polymer and the swelling characteristic of the polymer control the drug 
release rate4,15. 
2.1.3.3 Stimuli-responsive and Ion-exchange CRSs 
Some of the polymeric carriers can be activated to release their cargo by external stimuli 
including physical, chemical, magnetic, electrical, or mechanical stimuli that create cues 
for polymers with specific properties to be activated. These structures can be used for 
both targeted drug delivery and temporal CRSs. Several studies have been conducted on 
thermo-responsive, light-responsive, redox-responsive, pH-responsive, and enzyme-
responsive controlled release DDSs9. Figure 2-4C displays how physical stimuli can 
activate some responsive polymers to release their therapeutics. 
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Figure 2-4: Schematic illustration of A) Osmotic-controlled systems. Reproduced from Ref 4 
with permission. B) The swelling-controlled system. C) External physical stimuli to activate the 
responsive polymeric carriers to release their cargo in a controllable manner. Reproduced from 
Ref 9 with permission. 
Ion-exchange CRSs typically consist of resins made of cross-linked polymers with a 
considerable number of anionic and cationic functional groups. Body fluids can flow into 
their structure because of the cross-linked backbone of the polymer, and at the same time, 
the ionic part of the structure enables the ionic groups to exchange their mobile ions with 
another cation or anion16. Therefore, there are two types of ionic exchange DDSs: the 
release of cationic drugs using anionic resins, or release of anionic drugs using cationic 
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resins. Ionic strength, pH of the human body environment, and cross-link density of the 
resin can control the drug release rate4. 
2.1.3.4 Chemically-mediated CRSs 
Chemical reactions also play an integral role in controlling the release rate of drugs using 
polymeric systems. Chemically-controlled systems are generally divided into two groups: 
the pendant chain, and erosion-controlled systems. In pendant side chain systems, drugs 
are covalently linked to the polymer backbone with the polymers degrading once exposed 
to body fluids or water. The targeted site for delivering the drug has its own 
characteristics, which may lead to hydrolytic or enzymatic degradation of bonds between 
the drug and the polymer (Figure 2-5A). These systems can be used for targeted drug 
delivery. The rate of the hydrolysis and the enzymatic degradation rate of the drug-
polymer conjugation determines the rate by which the drugs detach from the polymer 
backbone4.  
In erodible controlled release polymeric systems, drugs are dispersed in a matrix and will 
be released upon degradation of the erodible polymer (Figure 2-5B). If the drug diffusion 
rate from the polymer is much faster than the erosion rate of the polymeric matrix, the 
kinetics of the drug release is diffusion-controlled, which is described in previous 
sections. If the diffusion rate of the drug through the polymer is lower than the erosion 
rate of the polymeric matrix, it would be erosion-controlled system17.  
There are two types of erosion mechanisms, namely bulk and surface erosion. Bulk 
eroding polymers are those that degrade from their bulk in contact with water because the 
permeation rate of the water molecules into the bulk of the polymer is faster than the 
erosion rate of the polymer. Surface eroding polymers are eroded from their surface, 
because of their faster erosion rate than the water penetration rate to their polymer bulk. 
In surface erosion, polymer moieties are detached from the surface of the polymer such 
that the size of the polymer decreases while preserving the initial geometry of the 
polymer (Figure 2-5C)6. 
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Figure 2-5: Schematic illustration of chemically-controlled release systems. A) Pendant side 
chain systems. B) Erosion controlled systems. Reproduced from Ref 4 with permission. C) 
Surface erosion versus bulk erosion mechanism. 
Although for biodegradable polymers, a combination of both mechanisms occurs 
depending on the chemical structure of the polymer backbone, most of the biodegradable 
polymers used for CRSs (e.g. famous polyesters) undergo bulk erosion. Since water can 
penetrate to the bulk of these polymers, the drug is not sufficiently protected during the 
treatment, and the predictability of the drug release kinetics during the bulk erosion is 
low. In contrast, surface eroding systems protect the water labile drugs as water cannot 
rapidly permeate to the bulk of the polymer. Another exciting characteristic of surface 
eroding polymers is their mechanical properties which do not change during erosion. 
Besides, the highly reproducible and predictable release kinetics of the surface eroding 
systems make them desirable for controlled DDSs6. 
Two types of biodegradable polymers predominantly undergo surface erosion: POEs and 
polyanhydrides. They both have highly labile functional groups leading to fast hydrolysis 
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on the surface, and because of the hydrophobic backbone, water cannot quickly pass 
through the bulk of the polymer. The majority of water at the surface of the polymer is 
consumed before water can penetrate the polymer bulk. POEs showed surface erosion in 
lower PHs conditions (in an acidic environment) while Polyanhydrides showed surface 
erosion in acidic, alkaline, and neutral environment which makes the polyanhydrides a 
desirable option to be used as a CRS18. 
Recent considerable progress in the development of advanced micro- and nano-scale 
DDSs has encouraged the use of erodible systems in small scales. The critical device 
dimension (Lcritical) is reported as a criterion for determining the type of erosion of a 
specific polymer. An erodible matrix with dimensions larger than Lcritical undergoes 
surface erosion; otherwise, it undergoes bulk erosion. The estimations of Lcritical for 
different polymers are available in the literature. The value of Lcritical for polyanhydrides 
was calculated to be 10−4 m, which is the smallest value reported for surface eroding 
polymers. It means that polyanhydrides undergo surface erosion down to almost 10-4 m, 
allowing for manufacturing erodible CRSs even in microscopic scales 19. 
2.2 Polyanhydrides 
Although Bucher and Slade had synthesized polyanhydrides for the first time in 1909, 
these polymers attracted more attention in the 1980s when Langer used them as 
controlled DDSs20. Polyanhydrides rapidly degrade in acidic, alkaline, and a neutral 
aqueous environment. In comparison to other hydrolytically degradable bonds such as 
amides and esters, anhydride bonds are more unstable and have the shortest average half-
life. Furthermore, polyanhydrides predominantly undergo surface erosion because of the 
hydrophobic backbone and hydrolytically unstable anhydride bonds in their structure. 
Due to the surface erosion mechanism, the release rate of the dispersed drugs in these 
polymeric systems ideally follows the erosion rate of the polymer. Because of these 
capabilities, they have a high potential to be used as controlled DDSs21. 
Despite many interesting properties of polyanhydrides for drug delivery applications, 
these polymers have not been used as often compared to other biodegradable polymers 
such as polyesters. The only US Food and Drug Administration (FDA)-approved product 
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made of polyanhydrides is the Gliadel Wafer (a polyanhydride-based implant for locally 
delivering the anticancer agent to a brain tumor)22. Difficulties involved in the synthesis 
of polyanhydrides are the main reason for their less popularity compared to other 
biodegradable polymers. 
2.2.1 Polyanhydrides’ Synthesis Pathways towards Radical 
Polymerization 
The high reactivity of anhydride functional groups in the vicinity of nucleophilic species, 
such as water causes difficulties in the synthesis of polyanhydrides. The most common 
pathway of synthesizing polyanhydrides is polycondensation. There are some limitations 
for polycondensation methods, including the very high temperature and the low pressure 
needed during the synthesis steps23. Domb et al. reported a method to synthesize 
polyanhydrides using coupling agents (phosgene and diphosgene) conducted at ambient 
temperature and eliminated the need for the purification steps required in 
polycondensation24. The limitation of this method is difficulties in removing the solvents 
such as toluene.  
Photopolymerization of methacrylate anhydride monomers was investigated by Langer 
group to achieve more manageable synthesis steps in addition to the capability of in vivo 
synthesis. The use of the methacrylate group in this study paved the way for utilizing the 
radical polymerization for synthesizing polyanhydrides. The radical polymerization can 
be initiated by thermal-, redox- or photo-initiators. Among these radical polymerization 
methods, photopolymerization undergoes a faster reaction while having a spatiotemporal 
control over the polymer synthesis23. In 2009 Shipp et al. 25 have synthesized a new 
photocrosslinkable polyanhydrides using thiol-ene polymerization under more 
straightforward conditions. Facile synthesis of these polyanhydrides in quite rapid 
reactions (around 15 minutes) using commercially available monomers alleviated the 
challenges in the synthesis of polyanhydrides reported in previous approaches. 
Thiol-ene polymerization, a type of click chemistry polymerization, is another radical 
polymerization process that has been used to synthesize polyanhydrides. The click 
chemistry is a method through which high yields of chemical species can be synthesized 
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in very rapid reactions while the reaction condition is simple26. It allows for the 
conversion of almost all monomers to higher molecular weight product in a simple way. 
Thiol-ene reactions can occur by the existence of radical initiators (thermal-, redox, or 
photo-initiators or a combination of these three). In thiol-ene reactions, the hydrogen 
atoms of the thiol moiety are abstracted and produce a thyl radical which is added to the 
alkene following an anti-Markonikov rule (Figure 2-6). Photo-crosslinking also allows 
for precise control over the polymer formation by directing the light source, and the 
reaction is quite rapid so that oxygen atoms do not have the chance to play a role in the 
reaction. This process generally takes from a few seconds to a few minutes21. 
 
Figure 2-6: The thiol-ene reaction scheme. 
2.2.2 Parameters affecting Polyanhydrides Erosion 
A desired erosion-controlled DDS is the one that can complete the drug release at the 
same time when erosion is completed. Depending on the ultimate application, this time 
can vary from a few hours to weeks or even years. Polyanhydride was used for controlled 
DDSs in the early 1980s as an alternative to PLA, and PLGA which can only release 
drugs over a few weeks20.  
As described in previous sections, biodegradable polymers typically undergo two types of 
erosion: bulk and surface erosion. The essential characteristic of polyanhydrides is their 
highly unstable anhydride groups in addition to their hydrophobic structure, leading to 
almost complete surface erosion. The drug release rate from surface-erodible polymers 
such as polyanhydrides is proportional to the external surface area of polymers. Near 
zero-order drug release rate (following the polymer linear mass loss kinetic) which is a 
desired release rate for the controlled release DDSs is achievable using this class of 
polymers27. The most critical measure for polymer erosion is known to be the polymer 
mass loss. For example, for a matrix with slab geometry, surface erosion means a linear 
mass loss profile28. 
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Different properties of polymers, including crystallinity, hydrophobicity, and water 
diffusivity, are dictated by polymer composition that affects the polymer erosion 
behavior29. By changing the monomers’ initial mole ratios, the degradation rate can be 
adjusted while the surface erosion maintains the dominant mode of erosion. Monomers 
with different hydrophobicity form polymers with various crystallinity. More crystalline 
structures have shown a lower erosion rate than the amorphous domains. The retarded 
water penetration to the polymer structure in the crystalline domain, cause this slower 
rate of erosion30. Shakeshef et al.31 prepared the poly (sebacic anhydride) (PSA) using 
melt polycondensation. They showed faster erosion rates for polyanhydrides with 
amorphous domains in comparison to more crystalline structures of the polymer with 
slower erosion rates. Adding drugs or model compounds to polyanhydrides may lower 
the cross-link density, leading to different erosion rates. For example, loading 2% bovine 
serum albumin to the poly (fumaric-co-sebacic anhydride) (p(FA-SA)) 20:80 
polyanhydride has shown increased degradation rate of the system32. Several studies have 
shown various erosion rates using different mole ratios of monomers. The copolymer of 
the SA and 1,3-bis( p-carboxyphenoxy)propane or p(CPP-SA) was used to develop the 
Gliadel wafer33. The slower erosion velocity of the p(CPP-SA) when it has more CPP in 
its structure28 is a good example of the effect of polymer composition on its erosion 
behavior. In another study, series of poly[bis( p-carboxyphenoxy)alkanes] made of six 
methylene units showed a very slower erosion rate in comparison to the polymer made of 
one methylene unit (three-fold decrease was observed in the release rate)30.  
Polyanhydrides erosion is also dependent on the pH and the temperature of the 
environment, the geometry of the polymeric DDS, and the flow rate of the media in 
contact with the polymer, besides the mentioned parameters.  
The pH of the solution might change the erosion of polyanhydrides. The in vitro 
degradation of the copolymer derived from SA and FA were conducted in Phosphate 
Buffered Saline (PBS) with different pHs by Santos et al.34. Three different polymers 
(p(FA-SA) 70:30, p(FA-SA) 50:50, and p(FA-SA) 20:80) were degraded at three pHs 
equal to 8.8, 7.4, and 4.2. Results showed significantly higher erosion rates of all three 
polymers at pH=8.8 than the neutral and acidic conditions. Besides, the degradation of 
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p(CPP) matrices at pH ranging from 7.4 to 10 showed more stability of polyanhydrides at 
lower pHs30. 
As polyanhydrides predominantly undergo surface erosion, the geometry of delivery 
systems made of polyanhydrides is of high importance. The erosion of polyanhydrides as 
microparticles are faster than the rate of erosion from macro-scale delivery systems made 
of polyanhydrides27. Another study showed the dependency of the amount of the water 
uptake for p(CPP-SA) 40:60 to the geometry and the size of the polyanhydride delivery 
system which can change the erosion kinetics of the polymer35.   
To better simulating the in vivo situation, shaking the PBS solution could be applied 
during in vitro experiments. This agitation is the representative of the mass transfer 
affecting the erosion of the polymer. Sheh et al.36 studied the effect of the mass transfer 
on Poly (fatty acid dimer: sebacic acid) (p(FAD:SA)) 50:50 by conducting the 
degradation test at three shaking rates (0, 60, and 120 rpm). No obvious differences were 
observed in this study for the erosion of this polymer with three different agitation 
speeds. Gopferich et al. and the Langer group have extensively studied the degradation 
and erosion of conventional polyanhydrides and parameters affecting their erosion 
behavior 27,37,38. 
2.2.3 Parameters affecting the Erosion of Photopolymerized Thiol-
ene Polyanhydrides 
Full characterization of a new polyanhydride and investigation of the impact of essential 
parameters on its erosion is necessary for the newly introduced polymer in order to be 
utilized as a CRS. In 2009, a new type of linear and cross-linked polyanhydrides was 
synthesized using thiol-ene chemistry. The advantages of synthesizing these 
photocrosslinkable elastomeric polyanhydrides over conventional polyanhydrides are 
discussed in section 2.2.1. Recently, few studies have been conducted to explore the 
erosion mechanism of this type of polyanhydrides. For the first time, Shipp et al.25 
synthesized linear and cross-linked polymers using 4-pentenoic anhydride (PNA), 3,6-
dioxa-1,8-dithiooctane (EGDT), and tetrakis(3-mercaptopropionate) (PETMP) monomers 
in the presence of a photo-initiator. They showed the surface erosion of this type of 
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polymer experimentally by measuring the mass loss of polymers in PBS at pH=7.4. Four 
different polymer compositions were synthesized to show different erosion times ranging 
from 30 to 70 hours. In another study, Rutherglen et al.39 characterized the same 
polymers thermo-mechanically for better understanding of the polymers’ properties. 
The erosion and toxicity study for a specific cross-linked thiol-ene polyanhydride made 
of PNA and PETMP were conducted by Poetz et al.40. In this study, they determined the 
mass loss profile of this polymer, showing an almost 10 hours induction period and total 
erosion time of 25 hours for a polymer with slab geometry (2 × 10 × 10 mm). The 
erosion front (the thickness of water penetration during the induction period) for this 
polymer was measured to be almost 400 μm. The variation of the pH in the media caused 
by the degradation products during the polymer erosion was monitored to calculate the 
hydrolysis rate as a function of the pH.  They also added 1wt% of a hydrophilic dye to 
the polymer and showed that the dye release profile qualitatively followed the mass loss 
profile of the polymer.  
In 2015, the same group41 synthesized a new semi-crystalline thiol-ene polyanhydrides 
with a broader range of erosion time starting from 24 hours to almost 10 days for 
polymers with cylindrical shape (10 mm diameter, 5 mm height). They showed the 
surface erosion of these polymers made of PNA, PETMP, and 1,6-hexanedithiol (HDT) 
with different initial mole ratios of monomers. In this study, the effect of the crystallinity 
of polymers on erosion time was investigated. Polymers with almost 60 % crystallinity 
showed ten times slower erosion rates than the polymer with the amorphous domain. 
Effect of adding various amounts of lidocaine (1, 2, and 3wt %) to polymers on the 
erosion of polymers showed slightly faster erosion for polymers loaded with drugs.  
There are essential parameters that substantially affect the erosion of thiol-ene 
polyanhydrides that have not been explored yet. In this thesis, a comprehensive study on 
erosion (mass loss) of different thiol-ene photopolymerized polyanhydrides was 
conducted and the effect of various factors on polymers’ mass loss and erosion rates is 
presented. The major part of chapter 3 of this thesis discusses the impact of parameters 
such as the temperature and pHs of media, the geometry of polymers, loading drugs or 
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model compounds to polymers, and media flow rate on erosion of cross-linked thiole-ene 
polyanhydrides. 
2.3 Diseases and Release Profiles 
Controlling the temporal profile of drug release is vital for achieving the optimal 
therapeutic effect. Despite significant advances in controlled release technologies, most 
of DDSs only offer monotonic, or constant (i.e., sustained) release profiles. However, 
different types of clinical circumstances require different types of timed-release. These 
temporal patterns are mostly defined by the effect of circadian rhythm on different 
clinical circumstances, giving rise to specific rhythms of medical conditions during the 
24 hours of the day. Besides, various factors, such as the patients’ condition, age, and 
gender necessitate patient-specific treatments via personalized medicine. 
2.3.1 Circadian Time Structure 
The study of the biological rhythm is called chronobiology, and the consequence of 
several biological rhythms is the temporal organization of human bodies. 
Suprachiasmatic nuclei (SCN) which are located in the hypothalamus control the human 
circadian rhythm42. Figure 2-7 illustrates the human circadian time structure. In this 
figure, sleep time is considered from 10:30 p.m. to 6:30 a.m. (the dark side) and the rest 
of the time during the 24 hours of the day is considered as activity time for a person with 
normal activity. The graph displays the peak of the basal gastric acid secretion and white 
blood cell count (WBC) at late night while the concentration of the hemoglobin and 
insulin is at the highest level at noon.  
This circadian rhythm governs the cells- to organs-level activities of our body, and hence 
affect the occurrence and even severity of medical conditions. For example, peptic ulcer 
attack and gall bladder occur mostly at night while the myocardial infarction (MI) or 
heart attack occurs most frequently in the morning. These patterns of the symptom’s 
severity show the necessity of precise treatments in which the exact amount of 
therapeutics are released in the body during exact times of the day, for specific durations. 
For example, Gonadotropin-releasing hormone (GnRH) necessitates pulsatile release for 
therapeutic effectiveness. Decreasing release profiles are beneficial for diseases that are 
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worse in the morning, including rheumatoid arthritis, asthma, and angina pectoris. 
Patients with osteoarthritis suffer from stronger pain in the afternoon and should benefit 
from an increasing release profile. Moreover, some agents or drugs require a particular 
administration profile during a specific period of time. For instance, patients who suffer 
from attention deficit hyperactivity disorder (ADHD) require a bimodal release profile of 
Ritalin-LA43. In addition to the temporal profile, for some drugs (e.g. anticoagulants, 
antihypertensives, and antiepileptics), achieving an accurate plasma concentration 
throughout the medication is very important due to the narrow therapeutic range and 
severe side effects. 
 
Figure 2-7: Human circadian time chart. Peaks of some biological features during 24 hours of 
the day in a person with normal daytime activity. The chart shows the Thyroid-stimulating 
hormone (TSH) as well as the growth hormone and melatonin peak in the bedtime while the 
concentration of the adrenocortical hormone (ACTH), follicle-stimulating hormone (FSH), and 
luteinizing hormone (LH) is at the highest level at the start of the daytime. Reproduced from Ref 
43 with permission. 
“Personalized medicine” in drug delivery systems has emerged as an approach to enhance 
the efficacy of treatments by designing customized therapy that follows the individual 
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patient’s needs. For example, a release profile that mimics the circadian rhythm of the 
patient is considered advantageous for insulin dosing and enables innovative methods in 
cancer treatment, highlighting the importance of developing CRSs that can adjust and 
customize the release profile for different circumstances. 
2.4 Recent Developments in Fabrication Methods of 
DDSs to Achieve Adjustable Release Profiles 
Several fabrication methods exist for manufacturing different DDSs. Although traditional 
compression tableting is still being used by pharmaceutical industries for manufacturing 
tablets and capsules44, increased awareness of individualized therapy and introduction of 
various biodegradable polymers with adjustable physicochemical properties, encourage 
the development of fabrication methods for manufacturing advanced controlled DDSs. In 
this section, recent developments in fabrication methods of advanced DDSs that enable 
releasing of drugs at controllable rates is reviewed. The focus of this section is on the 
micro-fabrication technique and the 3D printing technology that has attracted attention in 
recent years for the manufacturing of advanced controlled DDSs. 
2.4.1 Micro-fabrication Technology 
Micro-fabrication was originally adopted from the microelectronics industry and has been 
used for manufacturing advanced DDSs. Recently, micro-fabrication technology has been 
employed to manufacture high-throughput assays for drug discovery and tissue 
engineering applications45. Moreover, some issues of oral drug delivery can be addressed 
when micro-fabrication is used, owing to its ability to manufacture tiny features while 
providing control over the shape or geometry of delivery devices. 
2.4.1.1 Micro-fabrication Methods: Photolithography Process 
Micro-fabrication for creating delivery devices generally consist of repeated steps, 
including film deposition and photolithography. First, the desired two-dimensional (2D) 
features which are designed by a computer-aided design (CAD) software beforehand are 
printed as a photo-mask. Photolithography steps will in turn transfer the pattern to a 
substrate. In the first step, a photo-sensitive polymer coats the substrate to the desired 
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thickness. Then, the coated substrate is exposed to the Ultra Violet (UV) light while the 
photo-mask is located above the substrate and below the mask aligner (UV-light source). 
Finally, the cross-linked photo-resist encompasses embossed features, while the 
remaining uncross-linked polymer is washed away. Using the standard photolithography, 
it is possible to achieve features with fine resolution of 0.5 to 1 μm 46. 
Based on the ultimate application of these micron-sized features, a hard substrate such as 
silicon can be used as a master mold for making the inverse replica of soft elastomers. 
This process is called soft-lithography (Figure 2-8 A-F) in which usually poly 
(dimethylsiloxane) (PDMS) is used as the soft elastomer material 46. A combination of 
the micro-fabrication techniques such as standard photolithography with repeated replica 
molding steps allows for easy, rapid, and precise manufacturing of drug delivery devices 
at relatively low costs47,48. Fine features on a PDMS mold can be used to make channels 
through which minute amounts of fluid flow, creating a platform called microfluidics. 
Microfluidic devices have been extensively used for tissue engineering applications 
particularly for lab-on-a-chip studies, or as high-throughput platforms for drug screening. 
Microfluidics also has been used for fabrication of controlled release micro-particles as 
well as polymeric micro-containers in drug delivery devices 49. 
Several characteristics of micro-fabrication technology can help simplify achieving 
CRSs. Various devices have been micro-fabricated that are capable of delivering drugs 
locally, on-demand, or through programmable devices. Several papers reviewed various 
micro-fabricated controlled DDSs developed over the past 20 years50,51 covering both 
programed polymeric systems, on-demand or remotely programmable devices. 
Programmed polymeric systems are designed to deliver therapeutic contents in micro or 
nanoparticles at a pre-determined rate. The release of drugs from on-demand delivery 
devices is usually controlled remotely by operators. We review the advancement in the 
development of micro-fabricated programmable and on-demand devices designed for 
controlling the drug release profile. 
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2.4.1.2 Microchip DDS 
In oral dosage forms, many therapeutic molecules suffer from poor bioavailability and 
require other methods of delivery. Local DDSs that ensure the delivery of therapeutics to 
the proper site can enhance the effectiveness of treatment and potentially eliminate the 
harmful side effects to the liver that are often caused by oral means of delivery52. 
Implantable DDSs have attracted increasing attention for improving the local delivery 
and patient compliance.   
Figure 2-8: Schematic illustrations of the standard soft lithography process. A, B) The 
deposition of the photo-resist on a silicon wafer. C, D) the exposure of the coated substrate 
to the UV-light through the printed photo-mask. E) Pouring the PDMS on the embossed 
features of photoresist and peeling off the cured PDMS. F) Final PDMS molds containing 
designed features. Reproduced from Ref 46 with permission. 
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Microchips as CRSs were originally introduced by Robert Langer and coworkers53 and 
were designed to generate a long-term pulsatile release. Achieving pulsatile release is 
particularly important because the human body secretes molecules such as insulin3, 
growth hormone, and GnRH in a pulsatile manner. Accordingly, therapies targeting 
disorders related to these molecules need to be released in a pulsatile fashion to achieve 
an optimal therapeutic effect. In 1998, Robert Langer and his group conducted a proof-
of-concept study with a solid-state silicon microchip that could provide on-demand 
controlled release of substances. In this microchip, single or multiple chemical substances 
were entrapped in ~25nl reservoirs covered with thin gold membranes acting as anodes 
(Figure 2-9A). The release mechanism was based on the electrochemical dissolution of 
individual anode membranes upon application of voltage. The fabrication of the 
microchip was a sequential process of photolithography and microelectronic processing 
techniques. The proof-of-concept study indicated the ability of this model microchip to 
generate pulsatile release profiles of chemical substances53.  
In 2003, the Langer group proposed a similar platform for achieving pulsatile release in a 
programmed manner without requiring external stimuli to initiate the release.  Similar to 
the previous platform developed earlier, the device encapsulates single or multiple types 
of chemicals in 36 micro-sized reservoirs, covered with polymeric membranes on the one 
side (Figure 2-9B). The characteristics of this polymeric membrane that regulates its 
degradation rate (e.g., molecular weight, and compositions) determine the time of the 
release from the reservoir covered with this membrane. The reservoir-covering 
membranes are made of PLGA with various molecular weights, adjusting their rate of 
degradation and hence the time at which the chemicals (human growth hormone, dextran, 
and heparin) are released from each reservoir. The biodegradable polymeric device 
showed the ability to release four pulses of multiple chemicals over several months, and 
they successfully obtained a pulsatile release of bioactive heparin over 142 days (Figure 
2-9C, D)54. 
The increasing interest in implantable DDSs was followed by the work of Santini and 
coworkers on developing advanced on-demand and programmed microchip platforms55. 
In 2006, they further enhanced the membrane-covered reservoir design to achieve 
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remotely controlled pulsatile release of Leuprorelin protein over 6 months in dogs56. The 
release of the therapeutic protein from 100 individual reservoirs was regulated 
electrothermally, and controlled by telemetry. This method of membrane removal 
(electrothermal) is preferable over electrochemistry, because it is independent of the 
chemical compounds of the surrounding environment, as well as being considerably 
faster. The results for the in vivo experiment of the remotely-controlled microchips 
indicate the feasibility of the delivery of therapeutic polypeptides using implantable 
DDSs56. 
The first clinical trial of implantable microchip devices for drug delivery was carried out 
in 2012. The therapeutic compound delivered in this trial was an osteoporosis treatment 
(Human parathyroid hormone fragment, hPTH) that generally requires repeated injections 
of daily dosage and hence has low patient compliance. The microchip device used in this 
clinical trial has dimensions of 13.0 mm × 5.4 mm × 0.5 mm with 20, 600-nL wirelessly 
controlled reservoirs containing lyophilized hPTH. The microchips were implanted in 8 
women who were suffering from postmenopausal osteoporosis, in the subcutaneous space 
of the abdomen. The devices were implanted (Figure 2-9E) for four months and were 
controlled to deliver the once-daily dosage of the drug. The release of the reservoirs is 
controlled by a computer program that sends and receives information wirelessly to and 
from the implant, driving the precise timing of dose delivery. Microchip dosing proved 
capable of providing pharmacokinetic profiles similar to multiple subcutaneous 
injections, without the burden and pain of injections. This clinical trial demonstrated the 
potentials of this platform to improve current chronic delivery methods, e.g. repeated 
insulin injections for diabetic patients57,58. 
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Figure 2-9: Microchip controlled DDSs. A) The implantable silicon microchip device for 
controlling the release profile of the drug using the electrochemical dissolution of anodes, (i) a 
view cut showing the reservoirs (ii) enlarged view of a single conical reservoir. Reproduced from 
Ref 53 with permission. B) The schematic of the microchip device, including the reservoir-
containing substrate which is fabricated by a degradable polymer. C) Cumulative percentage of 
the initial loading of the C-dextran. Each symbol indicates the data from different devices in 
which the membranes are made of copolymers with different molecular weights. Increasing the 
molecular weight of the polymeric membranes caused the release times of the chemicals to 
increase. Arrows show the opening time for each membrane. D) Cumulative percentage of the 
initial loading of the H-heparin. Increasing the molecular weight of the polymeric membranes 
results in increased release times of the chemical. Reproduced from Ref 54 with permission. E) 
The final implantable microchip device and its location in the patients’ body to release the hPTH 
(1-34). Reproduced from Ref 57,58 with permission. 
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Implantable microchips are attractive means of drug delivery and have proved 
advantageous in different applications. However, these devices come with their 
limitations. Implantable means of delivery are inherently invasive, requiring implant 
surgery to place the DDSs and an explant surgery to remove the device from the body 
after the dosage is completed. Patients may need to take painkillers and/or anti-
inflammatory medications to alleviate the discomfort after surgeries. Current implantable 
DDSs have not incorporated measurements of the drug’s concentration after or during the 
release; however, a closed-loop control on the release from the device is necessary to 
avoid under- or over-dosing of the drug. In addition, the methods used for the opening of 
the reservoirs in proposed microchip devices are not reversible, and accordingly, quality 
assurance on whether the membrane will be appropriately removed as programmed or 
upon external stimulation, before implantation, has not been reported. In the clinical trial, 
patients tolerated the size of the implant, with the microchip device enclosing only 20 
reservoirs. An increased number of reservoirs is necessary for treatments requiring more 
frequent dosing and longer delivery periods, which may be associated with larger implant 
sizes. Despite attractive features implantable DDSs offer, their widespread development 
and use are constrained to these limitations, leaving oral dosage forms yet the most 
commonly used form of delivery57,1. 
2.4.2 3D Printing Technology for Manufacturing Oral Dosage 
Forms 
The oral routes of the drug administration are preferred by patients since they are 
affordable, noninvasive, and convenient for the patients. Accordingly, oral controlled 
DDSs have been the focus of many research work in personalized medicine1. 3D printing 
technology has emerged as an attractive fabrication method in the food and 
pharmaceutical industry due to its ability to manufacture objects with fine features. 
Modified-release and/or personalized oral dosage forms have been fabricated using 3D 
printing technology. The oral dosage forms are either directly 3D printed, or indirectly 
fabricated where molds or containers are 3D printed. Among various types of 3D printing 
technologies, powder-bed inkjet, fused deposition modeling (FDM), and 
stereolithography (SLA) have been the most commonly used methods for fabricating 
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solid oral dosage forms59. In what follows, a review on the application of these three 3D 
printing technologies in the fabrication of solid oral dosage forms for achieving 
adjustable release rates is presented. 
2.4.2.1 Powder-bed Inkjet 3D Printing 
The first 3D printer to receive FDA approval for pharmaceutical applications was 
Aprecia and was based on inkjet printing a binder solution on a power bed. It was used 
for printing tablets for epilepsy. The inkjet powder-bed 3D printing process (Figure 
2-10A) consists of spreading a powder layer onto a plate (bed) with a roller, and 
introduction of the binder solution to specific areas onto the powder to bind its particles 
in that area, based on the CAD design. This forms one layer of the structure of interest. 
The process is additive, meaning the same steps are repeated for each additional powder 
layer until the desired geometry is built. At last, the residual powder is brushed away. The 
structures fabricated by this 3D printing technology have high porosity which is 
beneficial for the production of immediate release tablets60.  
Cima and coworkers were one of the first groups that fabricated solid dosage forms using 
powder-bed 3D inkjet printing. They used standard pharmaceutical materials and varied 
the polymer contents to obtain delayed-release tablets. They fabricated tablets that 
underwent two different release mechanisms, namely erosion and diffusion. In erosion-
based tablets, by adjusting the quantity of the polymer, they achieved lag times (the time 
before the drug starts releasing) varying from 25 to 50mins (Figure 2-10B). Increased 
polymer content resulted in longer lag times and hence slower release. In tablets with a 
diffusion-based release, an increase in polymer content resulted in a reduction in the 
maximum rate of release. The lag time was not affected by polymer content in diffusion-
based tablets. The release profile characteristics were proved adjustable through 
modifying the quantity of polymer in inkjet 3D printers60.  
In a different study, they used the same powder-bed inkjet 3D printing system to develop 
four different solid dosage forms with distinct release behaviors61. The first tablet was 
designed for immediate/extended release pattern (Figure 2-10C-i). These tablets consisted 
of two sections, both loaded with chlorpheniramine maleate as the drug. The two sections 
33 
 
had different polymeric contents and hence had specific pH-sensitive release 
mechanisms. Experiments showed that the release of the drug from the first section 
happened with a 10min lag time, whereas the second section released the compound over 
an extended period of 7hrs (Figure 2-10D). The second dosage forms were breakaway 
tablets (Figure 2-10C-ii). These tablets were programmed to split into two drug-loaded 
sections by the fast erosion of a part separating the two. The drug-loaded sections erode 
in gastric fluid over a 30-45 min period. The third type of tablet was designed to achieve 
enteric dual-pulse release (Figure 2-10C-iii). A total amount of 3.4 mg diclofenac sodium 
was printed as two separate compartments into the tablet. As for the fabrication, they 
printed 6 layers of powder with only the binder, followed by a drug-containing layer. The 
same procedure was repeated, followed by two final layers of powder without drug. The 
release mechanism is erosion and hence the two diclofenac compartments are released in 
turn, making two pulses at 1 and 8 hours, as indicated by the release experiments results. 
The dual pulse devices were designed such that a portion of the drug be released in 
response to the low pH in the stomach whereas the rest would be released at high pH 
conditions in the intestine. The tablet design is showed in Figure 2-10C-iv61. 
In 2009, Yu et al. 62 reported powder-bed inkjet 3D printing of a doughnut-shaped DDS 
with zero-order release kinetics. The tablet design consisted of a model drug in the 
middle, and release-retardant material containing ethyl cellulose (EC) as the barrier 
covering the top, bottom, and outer surface of the tablet. The results of the release 
experiments indicated linear profiles, irrespective of the diameter of the central aperture, 
the outer diameter, or the table height. The release rate was adjustable by modifying the 
thickness, and quantity of EC of the outer surface covering the core. This study 
demonstrated the application of powder-bed 3D inkjet printing for achieving zero-order 
release kinetics throughout the entire dissolution process. 
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Figure 2-10: Directly printing the solid oral dosage forms using the powder-bed inkjet 3D 
printing process. A) The schematic illustration of the powder-bed inkjet 3D printing process. B) 
Variation of the lag times in releasing the chemicals by adjusting the content of the polymer. 
Reproduced from Ref 60 with permission. C) Four different tablets printed by the powder-bed 
inkjet 3D printer machine: schematics showing (i) immediate-extended release pattern tablet, (ii) 
the breakaway tablet, (iii) the enteric dual-pulse release tablet, and (iv) the dual-pulse release 
tablet. D) The release profile for the immediate-extended tablet. The first section made of E100 
20% w/w started releasing after 10 minutes (lag time). The second section made of Eudragit 
RLPO and acetone released its content over an extended period of 7 hours. Reproduced from Ref 
61 with permission. 
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In 2012, Genina et al. reported a novel method for fabricating solid dosage forms. It 
combines inkjet printing with flexographic printing to achieve controlled release patterns 
of therapeutics. They studied the impact of using three different paper substrates as 
porous carriers for DDSs on release characteristics. Release kinetic studies were 
conducted on tablets before and after coating various thickness of EC polymer film using 
flexographic printing. The release profile can be adjusted to decreasing or constant by 
changing the number of coating layers and/or the thickness of the coatings63. 
In 2017, Kyobula et al. reported a solvent-free 3D inkjet printing of solid dosage forms64. 
They fabricated matrix tablets containing a biocompatible and FDA approved wax as the 
carrier and a practically insoluble drug. In this study, they fabricated tablets with 
honeycomb geometries. They evaluated the ability to control the drug release profile by 
modifying the honeycomb characteristic, e.g. cell diameter and hence, the surface area. 
Larger than middle-sized honeycomb structures resulted in lower release rates due to a 
decrease in tablet surface area. This design allowed control over drug release rates by 
modifying the geometry65. 
2.4.2.2 Fused-deposition Modeling (FDM) 
Another type of 3D printing is fused-deposition modeling (FDM). In FDM methods, 
thermoplastic polymer filaments are extruded. Once filaments are in a melted semi-liquid 
form, they pass through a nozzle with elevated temperature. Filaments exit the heated 
nozzle and are deposited on the build plate on specified locations where they will be 
hardened. FDM 3D printing poses some advantages that made this technology suitable 
for manufacturing oral dosage forms. It can produce tablets with higher resolution 
compared to inkjet 3D printing, allowing for more accurate drug release. FDM-based 
machines are also capable of printing relatively intricate designs to achieve modified 
release profiles. More importantly, FDM 3D printing is easily set up and is relatively 
cheap59. Studies in which FDM-based 3D printers have been used to fabricate oral tablets 
can be divided into two classes: direct printing of tablets and printing containers/molds, 
helping the preparation of controlled-release tablets indirectly. A brief review of some 
studies in both categories is presented below.   
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Goyanes et al. fabricated tablets using the combination of FDM and hot-melt extrusion 
(HME) processing. They showed the potential of FDM technique in manufacturing oral 
dosage forms by producing tablets with different geometries, which is not easily 
achievable using conventional methods of tablet fabrication, e.g. powder compaction. 
They successfully printed tablets with five different geometries (Figure 2-11A). The 
filament was made of a water-soluble polymer (polyvinyl alcohol, PVA) loaded with 
paracetamol. They investigated the impact of tablet geometries, including the tablet 
surface area, volume, and the surface area to volume ratio (SA/V ratio) on drug release 
profiles by conducting separate experiments. Results showed that the fractional drug 
release rates were dependent on the SA/V ratio of the dosage forms. When the SA/V 
ratios for all the tablets were identical, almost all of them released 90 percent of their 
loaded drugs in 10 hours regardless of the differences in surface areas and the volumes of 
the tablets (Figure 2-11B). This study indicated the potential of FDM 3D printing as a 
low-cost fabrication process for manufacturing tablets with relatively complex 
geometries, which allows for controlling the release rate of the drug by adjusting the 
geometry of dosage forms66. 
In another study, Tagami et al. fabricated composite tablets using the FDM 3D printing 
method to tune the release rate of a model drug (calcein) loaded in PVA.  Filler 
components were either the water-soluble polymer (PVA) or a water-insoluble polymer 
(PLA) which did not contain any drug67. They used a dual nozzle 3D printer to print the 
drug component and the filler component separately. They produced different tablets with 
both PVA and PLA fillers (Figure 2-11C). By changing the thickness of the PLA, they 
could adjust the lag time. Results of in-vitro drug release tests indicated that an increased 
surface area increases the initial release rate of the model drug from the tablets. They 
designed two different shapes of the drug component with increasing and decreasing 
surface areas. Results indicated zero-order increasing and decreasing release rates, 
respectively. They also produced a cylindrical drug component with constant surface area 
and increased the thickness of the covering PVA to increase the lag time (Figure 2-11D). 
In addition, they showed the potential of the composite tablets to deliver drugs to certain 
locations through the GI tract by adjusting the release timing. Therefore, these tablets 
37 
 
with various wall thicknesses can be used as alternatives to pH-sensitive or other 
exogenously stimulated DDSs67. 
 
Figure 2-11: Direct FDM printing of oral tablets. A) Five different tablet geometries printed by 
FDM technique. B) Tablets released their contents in 2-3 hours when the SA/V ratio for all of 
them was the same. Reproduced from Ref 66 with permission. C) Eight calcein-loaded PVA/PVA 
composite tablets (top) and four calcein-loaded PVA/PLA composite tablets (bottom). D) By 
increasing the thickness of the covering layer, the lag time increased. Reproduced from Ref 67 
with permission. 
Despite the attractive properties of FDM for directly printing tablets and its potential for 
manufacturing the personalized treatments, it comes with certain limitations. FDM 
operation involves exposure of the polymer to high temperatures, which is only tolerated 
by thermoplastic polymers with a high glass transition temperature. These polymers have 
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relatively high molecular weights, and therefore the resultant structure exhibits extended-
release patterns that are not always suitable for patient dosage needs68.  
FDM can be used indirectly for manufacturing controlled-release tablets. In 2015, Andrea 
Gazzaniga and his group used FDM technology to explore the possibility of using 3D 
printing for fabricating Hydroxypropyl cellulose (HPC)-based capsular controlled DDSs. 
The capsular DDSs design consisted of a cap and a body. They obtained the release 
characteristics and evaluated the possibility of obtaining a pulsatile release with this 
design. Lag time (in this study is defined to be the time passed before 10% of the 
chemical is released), and pulse time (the time duration between release of 10% and 90% 
of the drug), were measured 70min and 10min, respectively. The results indicated the 
potential of FDM for rapid prototyping of capsular DDSs, and hence avoiding the time-
consuming process of mold development and enhancement69.   
Andrea Gazzaniga and his group improved the above design in an attempt to provide 
more flexibility with the capsular devices70. They modified the capsule design and 
composition to encapsulate different therapeutic compounds. The capsule was partitioned 
into two hollow halves, with the timing of release from each half independently during 
the capsule design by changing the thickness and/or composition of the compartment. 
Using combinations of compartment wall thickness and polymer characteristics, they 
could achieve immediate, enteric, and pulsatile releases. They obtained the release profile 
of the capsules, with compartments fabricated from PVA filaments with different 
thicknesses (Figure 2-12A). Release profiles of capsules with the same compartment 
thickness and different compartment compositions were also obtained (Figure 2-12B). 
This design can be particularly advantageous for improving patient compliance by 
ensuring the dosing schedule of prescribed with therapies that are not compatible or 
interact in gastrointestinal tract71.  
In another study, Sun et al.72 fabricated tablets using a commercially available FDM 
printer to achieve pre-determined release rates of drugs. They fabricated polymeric 
tablets within molds and containers created by extruded polymeric filaments. The 
impermeable container made of PLA was utilized to seal all surfaces of the drug-
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containing polymer. Drugs were released from the one side that was not covered by the 
container. Different release patterns were obtained from tablets due to the near zero-order 
erosion of polyanhydrides from the surface exposed to PBS. This design was also capable 
of incorporating two model drugs into one tablet and releasing them with different 
patterns. (Figure 2-12C, D). This study shows the potential of FDM 3D printing 
technology for creating containers and molds for achieving different tablet designs. 
 
Figure 2-12: FDM printing of containers and molds to create controlled-release tablets. A) The 
capsular DDS with different thicknesses, producing a two-pulse release profile. B) Two pulse 
release profile of the capsular DDS achieved by having two different materials for each 
compartment, with consistent thicknesses. Reproduced from Ref70 with permission. C) 
Customizable release rates of drugs (e.g., decreasing and pulsatile) from erodible tablets 
fabricated by containers and molds printed by FDM 3D printers. D) Tablets for releasing two 
drugs with different release rates at the same time. Reproduced from Ref 72 with permission. 
FDM is an interesting substitute for conventional fabrication methods of tablets due to its 
potential in manufacturing desired geometries to achieve a more accurate dosage. Unlike 
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conventional additive manufacturing methods, FDM can be used to create rounded 
corners which enhances patient compliance. However, there are limitations to this 
method which reduces its flexibility and wide-spread use. The high temperature required 
during FDM steps can damage thermally labile drugs. Besides, only a few biodegradable 
thermoplastic polymers can tolerate such high-temperature conditions. Although FDM 
has been used in fabrication of various geometries, the resolution of these printers may 
not be high enough to achieve the desired surface quality, as well as acute angles required 
in some dosage forms. 
2.4.2.3 Lithography-based 3D Printing 
Research on Stereolithography (SLA) 3D printing has been around since 1970s; however, 
Chuck Hull introduced the term in 1984 and was granted the patent for SLA in 1986. 
SLA technology is based on photopolymerization, that is, polymerization and hence 
solidification of the liquid resin upon exposure to laser. Photopolymerization is 
conducted in an additive manner (similar to other 3D printing technologies) where for 
each layer a CAD design guides the depth of the laser focus, obtaining localized 
photopolymerization, and eventually producing the 3D object of interest. SLA offers 
several advantages over other 3D printing technologies previously reviewed. In contrast 
to FDM methods, SLA does not expose the materials to high temperatures, and therefore 
it is suitable for fabricating DDSs with thermally labile therapeutics. SLA’s resolution is 
superior to other 3D printing technologies and is only restrained by the laser width73. 
Digital light processing (DLP) 3D printing is also a lithography-based method with 
higher resolution and printing speed in comparison to SLA 3D printing. Typically, a UV-
curable resin that can be printed by SLA would also be used in DLP. SLA utilizes lasers 
to cure the photo-curable solution point by point, while DLP uses a digital projector to 
cast and cure an entire slice of objects. Fast manufacturing times for the fabrication of 
complex structures with high resolution can be achieved by both methods, especially by 
DLP 3D printers. Recently, there has been increased attention to use DLP for 
manufacturing oral dosage forms74. 
The use of SLA technology for printing oral dosage forms was introduced by Simon 
Gaisford and Abdul W. Basit, and coworkers73. In this study, Polyethylene glycol 
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diacrylate (PEGDA) and polyethylene glycol 300 (PEG 300) were used as monomers in 
different ratios, aiming at obtaining different release kinetics at each ratio. The SLA 3D 
printed tablets with two different drugs (paracetamol and 4-ASA) are shown in Figure 
2-13A. Tablets were printed in torus shapes, which are complicated structures to achieve 
by other manufacturing methods. An increase in the PEGDA portion resulted in slower 
release rates. The release kinetics proved independent from changes in the pH, as shown 
in the release profile graphs (Figure 2-13B, C)73. This study proved the potential of SLA 
3D printing in the fabrication of high-resolution solid oral dosage forms from thermally 
labile drugs, with adjustable release rates to achieve immediate or extended profile. 
          
Figure 2-13: SLA printed tablet structure and release behavior. A) SLA printed tablets with 
paracetamol (top row) and 4-ASA (bottom row) as model drugs. Each row from left to right show 
tablets with PEGDA to PEG 300 ratios of 3.5:6.5, 6.5:3.5, and 9:1. B) The release profiles of the 
paracetamol from tablets with different polymer ratios. The release is slower for higher PEGDA 
percentages and is insensitive to changes in the pH. C) The release profiles of the 4-ASA. Slower 
release from higher PEGDS tablets was observed. The release showed independent from pH. 
Reproduced from Ref 73 with permission. 
SLA 3D printing technology has offered benefits over conventional 3D printing methods 
that are promising for further advances in fabricating personalized oral dosage forms. The 
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main limitation associated with SLA 3D printing, however, is the limited number of 
photocrosslinkable resins that are at the same time non-toxic, safe, and biocompatible. 
In this section, recent developments in the fabrication of advanced controlled DDSs for 
achieving various release profiles of drugs are reviewed. Micro-fabrication has been used 
to create microchip devices that are implanted in the body to release drugs with pre-
determined rates of release. Despite the high resolution of micro-fabrication methods and 
their ability to produce high-throughput platforms, several limitations of using 
implantable microchips (discussed in section 2.4.1.2), make the oral controlled DDSs the 
most desired option. Numerous studies such as studies reviewed in section 2.4.2 show 
substantial progress in the fabrication of polymeric oral tablets with adjustable release 
profiles using 3D printing technology. Most of the studies reported monotonic or constant 
release profiles of drugs, while some others achieved more complicated release profiles 
such as pulsatile release rates. The more complicated release patterns were achieved by 
more elaborate tablet designs and specific fabrication techniques, demonstrating the 
feasibility of creating tablets with various release patterns of drugs. Although these 
studies show that personalized medicine is no longer a dream, there exist some 
limitations in fabrication of modified release tablets that can hinder their widespread 
application. Some of these limitations can be addressed by improving the tablet designs 
and using appropriate fabrication methods. For example, the resolution of the fabrication 
method can determine the precision of the release rates. Micro-fabrication techniques 
such as photolithography are capable of creating miniaturized fine features with high 
resolution, whereas the resolution of the inexpensive and commercially available 3D 
printers such as FDM-based printers are not sufficient for printing tablets with complex 
geometries. SLA or DLP 3D printers have higher resolution for producing tablets; 
however, the limited number of printable materials that are compatible with these types 
of machines reduces their widespread application in producing controlled-release tablets. 
In addition, scalability and high-throughput manufacturing is a critical characteristic of 
any potentially successful fabrication method. High-throughput manufacturing is 
currently a significant challenge in production of advanced controlled DDSs with 
adjustable release rates. Most of the studies described in section 2.4.2, reported 
fabrication of a single tablet in each experiment, reducing the chances of their practical 
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use in clinical settings.  Manufacturing each tablet can take considerable amount of time, 
and the reproducibility level is low. 
2.5 Objectives 
The objectives of this study are to: 
(i) prepare and characterize surface eroding polymers used in the fabrication of drug-
loaded tablets, and to study the mass loss profile of the polymers comprehensively.   
(ii) develop a high-throughput fabrication platform for manufacturing the tablets that can 
provide adjustable drug release patterns. 
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Chapter 3  
3 A Comprehensive Study on Mass Loss Profile of Thiol-
ene Polyanhydrides  
In this chapter, we explore the effect of different parameters on mass loss (erosion) 
profiles of polyanhydrides synthesized by thiol-ene photopolymerization. A comparative 
study on release kinetic models fitting for better understanding of the polymers’ erosion 
behavior is also described. 
3.1 Materials and Methods 
3.1.1 Materials 
4-pentenoic anhydride (PNA), 2, 2-(Ethylenedioxy)diethanethiol (3,6-Dioxa-1,8-octane-
dithiol, EGDT), Pentaerythritol tetrakis(3-mercaptopropionate) (PETMP), 1-
Hydroxycyclohexyl phenyl ketone, and acid orange 10 (orange G) were purchased from 
Sigma Aldrich Chemical Co. and were used as received. 3D printer acrylate-based resin 
(Clear 2005T) was purchased from MiiCraft. Sylgard 184 Silicone Elastomer pre-
polymer and curing agent were purchased from Ellsworth Adhesive Chemical Co., for 
making PDMS. 
3.1.2 Polymer Synthesis Procedure 
1-Hydroxycyclohexyl phenyl ketone (photo-initiator, 0.1wt %) was weighed and placed 
into a 15 ml Falcon tube. Then, PNA was transferred into the tube, followed by the 
mixture of EGDT and PETMP.  The solution was mixed to obtain a homogenous 
mixture. The initial mole ratio of PNA to the total amount of monomers containing thiol 
groups (EGDT and PETMP) was 100:100. In this study, four different initial mole ratios 
of PNA to PETMP and EGDT were prepared and used including PNA: PETMP: EGDT = 
100:100:0, 100:75:25, 100:50:50, and 100:25:75. The homogenous mixture was then 
purged under the inert gas (nitrogen or argon) for 3 minutes and was transferred to PDMS 
molds. The pre-polymer solution in molds was exposed to UV-light (CL-1000 UVP 
Cross-linker) equipped with 365 nm UV lamps (intensity=~5 mW/cm2) for 5 minutes. 
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For some of the experiments, we added a model compound for which acid orange 10 (1-
3wt %) was weighted and added to the purged solution and mixed using sonication for 25 
minutes. Similar to the pre-polymer without the model compound, the dye-loaded 
solution was transferred to PDMS molds and was synthesized under the same UV-light 
for 5 to 15 minutes. The reaction scheme is presented in Appendix A-1. 
3.1.3 Polymer Characterization 
Four polymers with initial mole ratios of PNA to PETMP and EGDT were synthesized. 
The attenuated total reflectance Fourier-Transform Infrared Spectroscopy (ATR-FTIR) 
spectra were collected on a Bruker Vector 22 Infrared instrument. Differential Scanning 
Calorimetry (DSC) was performed using a DSC Q20 TA instrument. Samples of 
approximately 8 mg were placed in an aluminum Tzero pan where they underwent a 
heat/cool/heat profile at 10 °C min−1 under nitrogen (N2) atmosphere (50 mL min−1). Data 
was obtained from the final heat cycle of the heat/cool/heat profile. Before conducting the 
DSC experiments, the variation of the mass of samples was measured using the thermal 
gravimetric analysis (TGA) by a TA instrument Q50 TGA instrument under an atmosphere of 
N2 while the temperature was changing over time. Samples were put in a platinum pan and 
were heated at a rate of 10 °C min–1 under a flow of N2 (60 mL min–1). Water contact angles 
(WCAs) were measured by a Kruss DSA100 Drop Shape Analyzer. The WCAs were 
measured three times for bottom and three times for the top surface of each polymer, and the 
mean of these six measurements was calculated. Synthesized polyanhydrides were evaluated 
using the powder x-ray diffraction (PXRD) technique at room temperature. Rigaku-MiniFlex 
powder diffractometer (made in Japan) was used to collect PXRD data using Cu Ka (k = 
1.54059 Å) over the range of 0o < 2θ < 60o with a step width of 0.02o. The NIH ImageJ 
software (version 1.8.0) was used to measure polymer dimensions from photos taken by a 
Canon SX201 IS digital camera. The concentration of acid orange 10 in the solution was 
calculated using the absorbance measured by either a UV-visible spectrophotometry device 
(UV-VIS-NIR Spectrophotometer Shimadzu) or a micro-plate reader (Asys UVM 340) 
instrument. 
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3.1.4 Fabrication of 3D Printed Master Molds 
Polymers with different initial mole ratios of PNA to the PETMP and EGDT were 
synthesized in PDMS molds in order to be used for mass loss study. PDMS molds were 
fabricated using master molds printed by commercial DLP 3D printer (PICO2, ASIGA). 
Desired 3D models were designed by AutoCAD software and printed layer by layer from 
an UV-curable resin (Clear 2500T). The layer thickness was set as 250 µm, and the 
irradiation time for each layer was 5s. The 3D printed objects were treated using 
sonication in ethanol for 10 min and washed by Deionized (DI) water to remove any 
uncured polymer. 
3.1.5 Polymer Mass Loss 
The main focus of this chapter is on studying the mass loss profile of polyanhydrides 
synthesized by thiol-ene photopolymerization. Understanding of the mass loss profile is 
crucial for determining the erosion rate of the polymer, which is ideally proportional to 
the release rate of loaded drugs. The typical mass loss profile of this class of 
polyanhydrides is shown in Figure 3-1. This profile can be divided into two parts: the 
induction period and the erosion period. When polymers are immersed in the aqueous 
media, for a few hours they uptake some water (induction period), then start eroding until 
the completion of the polymer mass loss (erosion period).  
The mass loss profiles of polymers with different initial mole ratios of PNA to PETMP 
and EGDT were studied. Herein, the typical mass loss measurement method used during 
this study is described (unless otherwise specified). To obtain the mass loss profile, 
polymers were immersed in 5 ml PBS (pH=7.4) in glass vials, before being placed on a 
shaker (VWR micro-plate shaker). The shaker was set up at 37 °C with specific shaking 
rates (120 rpm). At certain time points (mostly every hour), the polymers were extracted 
from the solution, the water on the surface of the polymer was carefully wiped off using 
the disposable wipes (Kimwipes), and the dry polymer was weighted using the weight 
balance. 
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Figure 3-1: Mass loss profile of thiol-ene polyanhydrides for a cylindrical polymeric tablet. The 
mass loss profile consists of two main parts: the induction period, and subsequent erosion part. 
3.1.5.1 The Effect of Parameters on Mass Loss Profile of Thiol-ene 
Polyanhydrides 
As discussed in section 2.2.2, there are several parameters affecting the erosion of 
polyanhydrides. Various studies have been performed to examine the effect of different 
parameters on the erosion behavior of polyanhydrides (see section 2.2.2). Recently, a new 
type of polyanhydrides was synthesized using thiol-ene photopolymerization which is 
used in this thesis study. To our knowledge, the erosion behavior of this type of 
polyanhydrides under different parameters has not yet been studied. An extensive study 
on the effect of different parameters on mass loss (erosion) profile of this type of polymer 
was performed. 
In most of the experiments, the typical mass loss measurement described in section 3.1.5 
was used (unless otherwise specified). Briefly, the synthesized cylindrical polymers were 
placed into PBS at pH=7.4. For most of the experiments, the dimensions of cylindrical 
polymers were 8.7 mm × 8.7 mm (diameter × height). The shaker was set on 120 rpm 
and 37 °C to mimic the human gastrointestinal (GI) tract environment. The polymers 
were extracted from PBS and weighted at once every hour until the completion of the 
polymer mass loss. All experiments were conducted in triplicate. After measuring the 
mass of polymers over time, the remaining mass percentage and the fractional mass loss 
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percentage were calculated using Equation 3-1 and 3-2 where M0 is the initial mass of the 
polymer, and Mt is the polymer mass at time, t. 
𝑅𝑒𝑚𝑎𝑖𝑛𝑖𝑛𝑔 𝑚𝑎𝑠𝑠 𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 =  
Mt
M0
× 100, (3-1) 
𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛𝑎𝑙 𝑚𝑎𝑠𝑠 𝑙𝑜𝑠𝑠 𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 =  
M0 −  Mt
M0
× 100, (3-2) 
The parameters that were evaluated in this study for their effect on the polymer’s mass 
loss profile included: the temperature, agitation rate, and pH of the media, as well as the 
geometry and the composition of polymers. 
To explore the effect of polymer compositions on the mass loss profile, four different 
initial mole ratios of PETMP over EGDT (PETMP: EGDT = 100:0, 75:25, 50:50, and 
25:75) were used. After synthesizing polymers in cylindrical PDMS molds, experiment 
parameters were the same as explained in the previous paragraph, except for the 
temperature. This set of experiments was performed at room temperature. The previously 
described typical mass loss measurement was conducted for all of the polymers in this set 
until the vanishing of the polymers’ mass. In a similar set of experiments, the same 
procedures of mass loss measurements were conducted for the three polymers with initial 
mole ratios of PETMP: EGDT = 100:0, 75:25, and 50:50, this time at 37OC. By 
comparing the mass loss data obtained from these two sets of experiments, the effect of 
temperature on mass loss profiles of polymers was examined. 
The emergence of advanced fabrication techniques such as micro-fabrication technology 
and 3D printing made the fabrication of tablets with complex geometries easier. The 
importance of the tablet geometry on the polymer erosion and drug release can be studied 
by designing and fabricating of polymers with complicated geometries. The impact of the 
polymer geometry on the mass loss profile was investigated by fabricating several 
cylindrical polymers with different diameters and heights. Firstly, polymers made of two 
initial mole ratios of PETMP to EGDT of 100:0, and 75:25 were fabricated with diameter 
and height both equal to 3.3 mm. After measuring the polymers’ mass loss, the pattern of 
the mass loss profiles of the smaller polymers was compared to that of the bigger 
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polymers (diameter and height = 8.7 mm). This experiment also answers the question of 
whether the induction period and/or the mass-loss rates are affected by the substantial 
reduction in the volume of the cylindrical polymers from 𝜋(4.352 × 8.7) to 𝜋 (1.652 ×
3.3) with the same compositions.  
Three separate experiments were designed to examine the effect of the polymer surface 
area, volume, and surface area to volume (SA/V) ratio on the mass loss profile of the 
polymer containing PNA and PETMP monomers (EGDT was not used in this set of 
experiments). In the first experiment, two cylindrical polymers with the same surface area 
were fabricated, with the volume of one 36% higher than the other. In the second 
experiment, the volumes of the two cylinders were kept constant and the surface areas 
had a 44 % difference. Finally, two polymers with different surface areas and volumes, 
but equal SA/V ratios were fabricated.             
Oral tablets experience different pHs through the GI tract, and therefore investigating the 
impact of different pHs on erosion behavior of polymers that have potential applications 
in oral tablets is of high importance. Five PBS solutions with five different pH values 
(2.55, 4.27, 6.09, 7.41, and 7.98) were prepared to mimic the pH of different parts of GI 
tract. The mass loss measurement was conducted for polymer cubes (8.7×8.7×8.7mm) 
consists of PNA and PETMP monomers at room temperature.  
To investigate the effect of the mass transfer (mixing) on polymer mass loss profile, the 
polymers synthesized from PNA and PETM monomers were placed at different shaking 
rates (0, 60, and 120 rpm). These experiments help us understand the impact of the 
velocity of the solution on mass loss of the polymer. 
Adding drugs or model compounds changes the composition of the polymer, which can 
result in changes in the mass loss profile of polymers. Polymers made of PNA and 
PETMP were synthesized with and without the model compound.  In the latter case, acid 
orange 10, 1wt % was loaded in the polymer which was then synthesized under the UV-
light for 15 minutes. The mass loss measurements were conducted for both polymers. 
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3.1.5.2 Fitting Mass Loss Data 
Several studies have shown that polyanhydrides predominantly undergo surface 
erosion1,2. Researchers have shown that the linear mass loss profile of polyanhydrides 
results in a near zero-order drug release from these polymers3,4. Most of these studies 
used polyanhydrides in the form of a slab (a thin layer of polymer). Using the new type of 
polyanhydrides synthesized by thiol-ene photopolymerization, a rectangular slab 
(2× 10 × 10 mm) made of PNA and PETMP showed a linear mass loss profile. More 
complicated mass loss profiles were observed for a cube made of the same polymer 5. In 
this section, the behavior of the mass loss over time was examined. The data collected for 
polymeric cylinders and cubes made with mole ratios of PNA: PETMP: EGDT = 
100:100:0, 1:0.9:0.1, 1:0.75:0.25, 1:0.5:0.5, and 1:0.25:0.75 were fitted to linear, 
quadratic, and cubic equations and the r-squared values were compared to find the best-
fitted curve. 
3.1.5.3 Release Kinetic Models Fitting 
Mathematical modeling is a helpful tool to accelerate the development of pharmaceutical 
products. Mathematical models play an important role in understanding the 
physicochemical mechanisms governing the advanced CRSs and help with predicting the 
drug release rates. Prediction of the profile of drug release from polymers not only 
reduces the cost and time associated with experiments but also helps with providing 
effective therapies through using a more precise release rate of drugs6.  
There are numerous mathematical release kinetic models available for polymeric DDSs 
including the mechanistic or phenomenological, empirical, and semi-empirical models.  
Mechanistic release models for polymers that are predominantly controlled by diffusion 
mechanisms are extensively reviewed by Siepman et al7. Mechanistic models based on 
diffusion, dissolution, degradation and erosion mechanisms of polymeric DDSs that have 
used for the past 30 years have been reviewed by Fu and Kao et al.8. Various mechanisms 
affect the release of drugs from a solid oral dosage form, rendering mechanistic release 
modeling very complicated9. In advanced DDSs, various biomaterials with different 
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characteristics and complex geometries are employed and therefore current mechanistic 
models cannot adequately describe their drug release profiles. 
Empirical models are the equation-based mathematical models which are not dependent 
on physical or chemical laws. Semi-empirical models are based on empirical models; 
however, they can be explained by physical and/or chemical laws under certain 
conditions9. Empirical models have been frequently used because of the complexity of 
the mechanisms involved in drug release from DDSs. The drug release profile can be 
obtained by selecting the suitable model equation and estimating the model parameters 
based on experimental data.  
There are several release kinetic models available, among which zero-order, first-order, 
Higuchi, Korsmeyer-Peppas, Hixson-Crowell, Hofenberg, and Weibull, are the most 
commonly used for describing the release profile from polymeric systems10,11. As drug 
release rate from surface eroding polyanhydrides follows the polymer mass loss profile 
(i.e. it is proportional to the erosion rate of the polymer), release kinetic models fitting on 
the mass loss data for thiol-ene polyanhydrides were examined. Zero-order, first-order, 
Higuchi, Korsmeyer-Peppas, Hixon-Crowell, Hopfenberg, and Weibull kinetic models 
were studied. The mass loss measurements were conducted for polymeric cylinders and 
cubes with mole ratios of PNA: PETMP: EGDT = 1:1:0, 1:0.75:0.25, 1:0.5:0.5, and 
1:0.25:0.75. Mass loss data were fitted to these seven mathematical models using 
MATLAB MathWorks software. The coefficient of correlation R2 and the root mean 
squared error (RMSE) were used for verifying the fitting accuracy in order to find the 
best-fitted model. Below are brief explanations of each model and how each model is 
used to fit the mass loss data.  
The zero-order kinetic model describes a release system where the drug is released at a 
constant rate regardless of its concentration. Equation 3-3 shows the zero-order release 
kinetic model where 𝐶0 is the initial amount of the drug in the solution, 𝐶𝑡 is the total 
released drug until time 𝑡, and 𝐾0 is the zero-order rate constant. Most of the transdermal 
systems and some tablet matrix systems containing drugs with low solubility are the 
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examples of zero-order release kinetics applications12.  Here, the zero-order model 
described in Equation 3-3 to the measured cumulative mass released over time is used. 
𝐶𝑡 = 𝐶0 − 𝐾0𝑡  (3-3) 
The first-order model describes concentration-dependent release behavior. Equation 3-4 
shows the first-order kinetics model where 𝐶𝑡 is the total released drug until time 𝑡, and 𝐾 
is the first-order rate constant. Equation 3-4 can be reorganized to another form of first-
order release kinetics model which is shown in Equation 3-5 where 𝐶0 is the initial 
concentration of drug in the solution. The main application of this model is for water-
soluble drug-loaded dosage forms in porous structures13. The log of the remaining mass 
percentage (calculated by Equation 3-1) versus time to the first-order model (Equation 3-
4) gives a straight line with a slope of 
−𝐾𝑡
2.303
. 
𝑑𝐶𝑡
𝑑𝑡
= −𝐾𝐶   (3-4) 
𝑙𝑜𝑔𝐶𝑡 = 𝑙𝑜𝑔𝐶0 −
𝐾𝑡
2.303
 (3-5) 
The first and most commonly used mathematical model for describing the drug release 
rate from matrices have been developed by Higuchi14 in 1961. At first, the model was 
only developed for planar systems which was later modified to a more complicated 
equation that considers porous polymers in different geometries15. The basic Higuchi 
model is shown in Equation 3-6 where 𝐶  is the amount of the drug release per unit area 
of the matrix, 𝐷 is the diffusion coefficient for the drug in the matrix, 𝑞𝑡 is the total 
amount of drug in a unit volume of matrix, 𝐶𝑆 is the dimensional solubility of drug in the 
polymer matrix, and 𝑡 is the time. Higuchi model can be simplified to Equation 3-7, 
which relates the cumulative drug release (the total released drug until time 𝑡) to the 
square root of time by Higuchi constant (𝐾𝐻). The measured cumulative amount of mass 
released verses square root of time was fitted to Equation 3-7. 
𝐶 = [𝐷(2𝑞𝑡 − 𝐶𝑆)𝐶𝑆𝑡]
1
2 (3-6) 
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𝐶𝑡
𝐶∞
= 𝐾𝐻𝑡
1
2 (3-7) 
The power law is a semi-empirical model that relates drug release with time 
exponentially, as described by Equation 3-8. Korsmeyer-Peppas equation16 was 
developed in 1983 for drug release from hydrophilic polymers as shown in Equation 3-9 
where 
𝐶𝑡
𝐶∞
  is the drug release fraction at time = 𝑡 , 𝐾  is the rate constant, and n is the 
release exponent. By deriving the release exponent 𝑛 (ranging from 0 to 1), the release 
mechanism of the polymeric system with certain geometry can be interpreted 17. To find 
the release mechanism, the first 60% of mass loss data calculated from Equation 3-2 were 
fitted to the Korsmeyer-Peppas model (Equation 3-8). 
𝐶𝑡
𝐶∞
= 𝐾𝑡𝑛  (3-8) 
The above equation can also be written as: 
𝑙𝑜𝑔
𝐶𝑡
𝐶∞
= 𝑙𝑜𝑔𝐾 + 𝑛 𝑙𝑜𝑔 𝑡 (3-9) 
In 1931, Hixson-Crowell model was developed18 with the argument that the surface area 
of a group of particles is proportional to the cubic root of their volume. Equation 3-10 
describes their model. 𝐶0 is the initial amount of the drug, 𝐶𝑡 is the total amount of the 
drug released by time t, and 𝐾𝐻𝐶 is the Hixson-Crowell rate constant. This model 
describes the systems in which the surface area and diameter of particles or tablets 
change over time. In this study, the measured remaining mass percentage versus cubic 
root of time was fitted to the Hixson-Crowell model. 
𝐶0
1
3 − 𝐶𝑡
1
3 = 𝐾𝐻𝐶𝑡 (3-10) 
Hopfenberg model describes drug release from erodible systems with different 
geometries. In Hopfenberg model, the release rate is proportional to the surface area of 
the system. Equation 3-11 shows the Hopfenberg empirical equation where 𝐶∞ is the 
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initial amount of drug-loaded in the system, 𝐶𝑡 is the amount of drug released at time 𝑡, 
𝐾0 is the rate constant of surface erosion process, 𝑎 is the half-thickness (half-thickness 
in case of slab or radius in case of cylinders or spheres), 𝐶𝑙 is the initial drug 
concentration in the system, and 𝑛 is the release exponent (𝑛 = 1 for slab, 𝑛 = 2 for 
cylindrical, and 𝑛 = 3 for spherical geometries) 19. In this study, the fractional mass 
release (mass loss) versus time was fitted to Hopfenberg model with 𝑛 = 1 for cubic and 
𝑛 = 2 for cylindrical tablets. 
𝐶𝑡
𝐶∞
= 1 − [1 −
𝐾0𝑡
𝐶𝑙𝑎
]
𝑛
 (3-11) 
The Weibull kinetic model is another empirical model which can be used for dissolution 
and releasing drugs from oral dosage forms20. Weibull model is shown in Equation 3-12 
where 𝐶0 is the total amount of drug released, 𝐶  is the amount of the drug dissolved at 
time 𝑡, 𝑇 is the lag time, 𝑎 is the scale parameter, and 𝑏 is the release curve shape. The 
fractional mass release (mass loss) verses time were fitted to Weibull model (Equation 3-
12). 
𝐶 = 𝐶0 [1 − 𝑒
−(𝑡−𝑇)𝑏
𝑎 ] (3-12) 
Table 3-1 summarizes all the above-mentioned release kinetic models’ equations with a 
brief description of their release mechanisms. 
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Table 3-1: Release kinetic mathematical models 12,21–23. 
 
 
3.2 Results and Discussion 
This section presents and discusses the results of the experiments conducted for studying 
the mass loss profile of the polyanhydrides synthesized using thiol-ene 
photopolymerization as well as the results for kinetic models fitting study. 
 
Model Mathematical Equation Release Mechanism 
Zero order 
 
𝐶 = 𝐶0 − 𝐾0𝑡 
 
Diffusion mechanism 
First Order 𝑙𝑜𝑔𝐶 = 𝑙𝑜𝑔𝐶0 −
𝐾𝑡
2.303
 
 
Diffusion mechanism 
Fick’s first law 
Higuchi 
 
𝐶 = [𝐷(2𝑞𝑡 − 𝐶𝑆)𝐶𝑆𝑡]
1
2 
or 
𝐶𝑡
𝐶∞
= 𝐾𝐻𝑡
1
2 
 
 
 
Diffusion-based mechanism 
Fick’s first law 
 
 
Korsmeyer-Peppas 
 
Power Law 
 
𝑙𝑜𝑔
𝐶𝑡
𝐶∞
= 𝑙𝑜𝑔𝐾 + 𝑛 𝑙𝑜𝑔𝑡 
𝐶𝑡
𝐶∞
= 𝐾𝑡𝑛  
 
Semi empirical model 
Diffusion mechanism 
 
Hixson-Crowell 𝐶0
1
3 − 𝐶𝑡
1
3 = 𝐾𝐻𝐶𝑡 
 
Erosion mechanism 
Mechanistic model 
Hopfenberg 
𝐶𝑡
𝐶∞
= 1 − [1 −
𝐾0𝑡
𝐶𝑙 𝑎
]
𝑛
 
 
Erosion mechanism 
Empirical and mechanistic 
model 
Weibull 
𝐶 = 𝐶0 [1 − 𝑒
−(𝑡−𝑇)𝑏
𝑎 ] 
 
Empirical model 
 Life-time distribution 
function 
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3.2.1 Polymer Preparation and Characterization 
Cross-linked polyanhydrides were synthesized using thiol-ene photopolymerization 
reaction. ATR-FTIR results showed the absence of thiol and vinyl peaks at 2565 cm-1 and 
1640-1650 cm-1, respectively. It also specified the dual peaks of anhydride functional 
groups at 1730-1740 cm-1. These peaks indicate that almost all the thiol and vinyl 
functional groups were reacted. The FTIR spectra, which is shown in Appendix A-2 is in 
agreement with the FTIR data obtained by Rutherglen et al.24 for the same polymers. 
PXRD was used to show the crystallinity of polymers. PXRD data (Figure 3-2) for all 
synthesized polymers demonstrated the amorphous domains of the polymers’ structure. 
Amorphous polymers do not contain the periodically arranged atoms, unlike the 
crystalline polymers. In amorphous structures with atoms distributed randomly, the X-ray 
scatters in different directions, resulting in a large bump in the FTIR spectrum in a wide 
range (2θ). In contrast, in crystalline structures, there are sharp peaks with high intensity 
which are narrow at some points (periodically arranged atoms result in scattered X-ray in 
certain directions)25. Semi-crystalline structures have both the large bump and narrow 
peaks in their PXRD pattern such as the semi-crystalline polyanhydrides synthesized by 
Poetz et al.26. The XRD results indicate the same large bumps without any sharp peaks 
with high intensity for all polymers, showing their amorphous domains. 
TGA studies demonstrated that synthesized polyanhydrides (PNA: PETMP: EGDT = 
100:100:0, 100:75:25, 100:50:50, 100:25:75), had thermal stability with the onset of 
decomposition observed at 329 °C, 328 °C, 324 °C, and 317 °C respectively (Appendix 
A-3). High stability of the samples allowed conducting DSC experiments. DSC was 
conducted to obtain the glass transition temperature (Tg) of each polymer. Tg values 
were specified from the second cycle of heat/cool steps to be -25.1°C, -36.6°C, -48.9°C, 
and -55.8°C respectively which are similar to Tg values previously reported using 
dynamic mechanical analysis (DMA)24. Besides, DSC results did not display any 
crystalline melt temperature (Tm), which confirmed the results of PXRD regarding the 
amorphousness of the polymers’ domains (Appendix A-4).  
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Hydrophobicity of four polymers (PNA: PETMP: EGDT = 100:100:0, 100:75:25, 
100:50:50, 100:25:75) was also evaluated using the water contact angle measurement. 
The angle between the water droplet and the top and bottom surfaces of the synthesized 
polymers were measured three times for each side of the surface. The mean of the six 
measurements for each polymer was calculated to be 81.8° ± 4.8, 72.0° ± 7.0, 68.5°± 8.5, 
and 63.5° ± 7.3, respectively. A water contact angle smaller than 90o shows a relative 
hydrophilic solid surface whereas angles higher than 90o show a hydrophobic surface. A 
decrease in the water contact angle values is observed with increased EGDT to PETMP 
initial mole ratios. The reason is known to be the higher cross-link density of polymers 
with higher initial mole ratios of PETMP 24. The range of the measured water contact 
angles (from 64° to 82°) is in agreement with other surface-erodible polymers27 and 
polyanhydrides in particular28. 
3.2.2 Polymer Mass Loss Profile 
In this section, the impact of various parameters on the mass loss profile of thiol-ene 
polyanhydrides is investigated. 
Figure 3-2: PXRD patterns of four thiol-ene polyanhydrides. 
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3.2.2.1 The Impact of Polymer Composition 
The remaining mass percentage (Figure 3-3A), as well as the fractional mass loss 
percentage (Figure 3-3B) were plotted for all four polymers. Mass loss profiles showed 
approximately 10 hours of induction period, which is in close agreement with the results 
obtained by Ship et al.29 for the same polymers. Total erosion times ranged from 20h to 
50h. Figure 3A indicates that an increased initial mole ratio of EGDT results in a shorter 
total erosion time. Figure 3B also indicates faster erosion rates for polymers with higher 
mole ratios of EGDT against PETMP in their networks. However, induction periods did 
not change by changing the polymer composition using different mole ratios of 
monomers.  
The primary reason for differences in erosion rates is known to be the cross-linking 
density of polymers. The cross-linking density decreases with an increased ratio of 
EGDT26. Another reason could be the crystallinity of the polymers since, as discussed in 
section 2.2.3, polyanhydrides with higher crystallinity show lower erosion rates than 
polyanhydrides with amorphous domains26,30. PXRD and DSC were used to evaluate the 
level of the crystallinity of four polymers. As explained in section 3.2.1, PXRD data 
displayed the amorphous domains for these polymers, and DSC data did not show any 
Tm, that confirms the lack of the crystallinity in their structures. Water contact angles 
were also measured to obtain the relative hydrophobicity of polymers as another potential 
reason for different erosion rates observed in mass loss profiles of our four different 
polymers. Results for water contact angles measurements are discussed in detail in 
section 3.2.2.1. Table 3-2 summarizes the results of experiments performed to explore the 
reasons behind different erosion rates of different polymer compositions as well as the 
cross-link density of polymers obtained from Ref26. 
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Figure 3-3: The impact of polymer compositions on mass loss profiles. A) Remaining mass 
percentage and B) Fractional mass loss percentage of thiol-ene based polyanhydrides. Increasing 
the EGDT in polymer networks leads to faster erosion rates. However, changing the mole ratios 
of EGDT over PETMP did not change the induction periods. 
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Table 3-2: Properties of polymers obtained from experiments for exploring 
 reasons for the change in erosion rates of different compositions of polymers. 
 
3.2.2.2 The Effect of Temperature 
The reactions occurring between polymer bonds in contact with the aqueous media drive 
degradation of biodegradable polymers. Temperature can change the reaction rates and 
consequently change the erosion rate of polymers. The impact of temperature on 
polymers’ mass loss profiles was investigated by measuring the mass loss of polymers in 
PBS set at two different temperatures (the ambient temperature (25°C) and the 
physiological temperature (37°C)). Figure 3-4 compares the results by showing the mass 
loss data for polymers at the two temperatures. The induction period was reduced from 
approximately 10 hours to 5 hours at a higher temperature for all polymers. Erosion rates 
were considerably higher at PBS with 37°C in comparison to the room temperature 
environment. The acceleration of degradation rates by elevation of the temperature for 
biodegradable polymers such as PLA and PLGA have reported in several studies 31–33. 
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Figure 3-4: The impact of temperature on polymer mass loss profile. The remaining mass 
percentage of A) Four polymer compositions at room temperature. B) Three polymer 
compositions at 37°C. Higher temperature leads to shorter induction periods and shorter erosion 
times. 
3.2.2.3 The Effect of Tablet Geometry 
First, the mass loss data for two small cylindrical polymers were compared to the mass 
loss of the larger polymers with the same compositions. Results show a similar induction 
period (~5hours) for smaller polymers compared to the larger ones (Figure 3-4). The 
total erosion times for the smaller and larger polymers reduced from 17h to 13h and 9h to 
6.5h when PETMP: EGDT = 100:0 was changed to PETMP: EGDT = 75:25, 
respectively. The reason for shorter total erosion times for the smaller tablets is their 
reduced mass, which erodes entirely in a shorter time. Results of a study conducted by 
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Akbari et al. show similar changes to the induction periods and mass loss rates when the 
effect of different geometries of p(CPP:SA) on mass loss profiles was examined34.  
Similar patterns of the mass loss profile observed for both tablet geometries in our study 
confirms that thiol-ene polyanhydrides’ maintain their surface erosion behavior even at 
very small sizes. This observation agrees with previous findings regarding the very small 
critical device dimension value for polyanhydrides (discussed in section 2.1.3.4)4. Results 
indicate the high potential of this type of polyanhydrides to be used for various 
applications that require small size DDSs such as mini-tablets to benefit pediatric 
patients35. 
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Figure 3-5: Impact of tablet geometry. The remaining mass percentage for bigger cylindrical 
tablets (diameter and height equal to 8.7mm) (A) and smaller cylindrical tablets (diameter and 
height equal to 3.3mm) (B). 
The effect of the tablet surface area, volume, and SA/V ratio on the mass loss rates and 
induction periods of two cylindrical tablets with the same polymer compositions was also 
studied. The induction periods for the tablets with the same surface areas and different 
volumes were similar (~5hours), while the total erosion time for the tablet with lower 
volume was shorter. The reason is that the mass of the smaller volume tablet is less than 
the other tablet. Although both tablets had similar induction periods, the cylindrical 
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polymer with higher volume has taken longer to erode, with a slower remaining mass loss 
percentage rate as shown in Figure 3-6. 
                       
Figure 3-6: Impact of geometry on the mass loss profile of polymers. A) Remaining mass 
percentage of two tablets with the same surface areas and different volumes (V1 = 1.36 V2). B) 
Schematics of tablet designs and dimensions. 
To explore the effect of the surface area on mass loss profiles, two cylindrical tablets 
were designed and fabricated with same volumes but different surface areas. The mass 
loss data for both tablets show similar induction periods; however, the mass-loss rate for 
the tablet with 44% higher surface area is faster. Although in this case the total mass of 
both tablets was initially the same, the tablet with a higher surface area exposed to PBS, 
showed faster mass loss rate and consequently higher erosion rate (Figure 3-7). Results 
show that the same total amount of drugs can be delivered at different rates by changing 
the surface areas of the tablet and keeping the volumes constant. 
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Finally, two tablets with different surface areas and volumes were fabricated. For both 
tablets, the SA/V ratio was equal to 0.69. Although one of the tablets (the orange tablet in 
Figure 3-7 B) had a higher surface area and higher total volume, the mass loss data of 
both tablets closely follow each other as shown in Figure 3-8A with similar mass loss 
percentage rates. In addition, no change is observed in induction periods of the two 
tablets.  
Results show the importance of the SA/V ratio of the tablet for determining the mass loss 
percentage rates of polymers. The induction period was not affected by the tablet 
geometries, while the mass-loss rate for a polymer with higher surface area and lower 
volume was shown to be faster. Polymers with the same SA/V ratios showed similar 
mass loss percentage rates despite the higher volume and larger surface area of one tablet 
against the other. Recently, the importance of the SA/V ratio of tablets has been studied 
by researchers, and their results agree with our findings. For example, Goyans et al. 
showed that the fractional drug release from an erosion mediated controlled-release 
tablet, made of PVA filaments, is only dependent on the SA/V ratio rather than the 
surface area or the volume separately36. Martinez et al. performed a dissolution test on 
Figure 3-7: Impact of geometry on the mass loss profile of polymers. A) Remaining mass 
percentage of two tablets with the same volumes and different surface areas. B) Schematics of 
tablet designs and dimensions. 
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various tablet geometries with the same SA/V ratios. Tablets with similar SA/V ratios 
resulted in a similar fractional drug release rate, while tablets with same surface areas 
showed different fractional release rates. They also showed an increase in dissolution 
rates of tablets by increasing the SA/V ratio of tablets, which were made of polyethylene 
glycol diacrylate (PEGda) 37. The similar results have been obtained for a controlled-
release tablet made of hydroxypropylmethylcellulose (HPMC)38. 
                   
Figure 3-8: Impact of geometry on the mass loss profile of polymer. A) Remaining mass 
percentage of two tablets with the same SA/V ratio while both surface areas and volumes are 
different. B) Schematics of tablet designs and dimensions. 
3.2.2.4 The Effect of pH 
Oral tablets reside in different parts of the GI tract for specific time intervals at various 
pHs ranging from 1-2.5 at the stomach to 7.88 at the distal small intestine (Figure 3-9A). 
Therefore, the effect of pH on mass loss profile of a thiol-ene polyanhydride made of 
PNA and PETMP was studied. The induction periods and mass loss rates were similar for 
all samples except for the one in pH=7.89, which showed shorter induction period and 
faster mass loss rate. The faster mass loss rate of the polymer in alkaline solution is in 
close agreement with studies that showed acceleration in degradation of biodegradable 
polymers in more alkaline environment39,40. Considering the induction period that lasts a 
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few hours and based on the mass loss data obtained from different pHs, it can be assumed 
that a tablet made of this polymer will pass the parts of the GI tract with acidic 
environment, and will reside in pHs around 7 while eroding. 
 
Figure 3-9: Impact of pHs on mass loss profile of polymers. A) Schematic representation of GI 
tract pathway with various pHs. Reproduced from Ref 41 with permission. B) Remaining mass 
percentage of polymers in provided solutions with different pHs. 
3.2.2.5 The Effect of Mass Transfer 
To explore the effect of mass transfer on the polymer mass loss profile, various shaking 
rates were used. Different shaking rates create different convective forces in PBS that can 
change the reaction rates by carrying the detached monomers away from the polymeric 
tablets. The induction periods and erosion rates stayed similar, with a slightly slower 
erosion rate at 0 rpm shaking rate (Figure 3-10). These findings indicate the non-
significant effect of shaking rates on polymer mass loss profile. Shieh et al.42 found a 
similar trend in their study on p(FDA:SA) polyanhydrides. 
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Figure 3-10: Mass transfer effect on the polymer mass loss profile. Different shaking rates (0, 
60, 120 rpm) were used. 
3.2.2.6 The Effect of adding a Model Compound 
Adding drugs to the polymer change some physicochemical properties of polymers that 
may cause changes in polymer degradation. The polymer and the dye-loaded polymer are 
shown in Figure 3-11. Results of the mass loss for the two tablets indicate no 
considerable differences in the induction periods and the mass loss rates (Figure 3-11). 
During the final five hours of the erosion period, the polymer containing the model 
compound eroded very fast (see the orange line in Figure 3-11). This is potentially due to 
the presence of uncross-linked monomers in the center of the dye-loaded polymer that 
indicates a reduction in the penetration depth of the UV-light in the dye-loaded polymer. 
To obtain the same behavior for the dye-loaded polymer as the other polymer, the 
polymer loaded with dye should be put under the UV-light for longer times, or at higher 
intensities. 
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Figure 3-11: Effect of adding the model compound to the polymer on mass loss profile. 
3.2.2.7 Pre-Erosion for Eliminating the Induction Period 
The induction period (or lag time) during which polymer only absorbs some water lowers 
the predictability of the polymer mass loss and therefore is undesired. In addition, for 
treating some diseases, the drug needs to start releasing as soon as the patient swallows 
the tablet. For eliminating the induction period, a pre-erosion experiment was performed. 
The cylindrical polymers made of initial mole ratios of PNA: PETMP: EGDT = 
100:75:25 were immersed in PBS for 8 hours. The polymers were extracted from the 
solution after the induction period and when the erosion had been started and were put 
under the vacuum for 10 hours. After 10 hours, the polymers were again placed in PBS 
and the mass loss measurements were carried out. Figure 3-12 indicates how the mass 
loss of the samples after pre-erosion follows the mass loss profile of the samples that 
were not pre-eroded. This finding shows that the induction period can be removed for this 
polymer by means of the pre-erosion process. Langer group studied the elimination of the 
lag time for Poly[bis(p-carboxyphenoxy)methane (PCPM) polyanhydride by pre-eroding 
it for 50 hours at 60 °C 43.  
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Results for pre-erosion experiments showed that when the polymer is placed in PBS 
again, after pre-erosion and vacuuming, the polymer continues the erosion from where it 
left off, instead of undergoing a second induction period.  This can be attributed to a 
decrease in the hydrophobicity of the polymer surface due to hydrolysis when it is in 
contact with PBS in the pre-erosion period. This experiment was a proof of concept for 
the feasibility of eliminating the induction period for thiol-ene polyanhydrides. Further 
experiments should be designed and performed to further investigate the elimination of 
the induction period using the mentioned pre-erosion process. 
 
Figure 3-12: The pre-erosion process to eliminate the induction period.  
3.2.2.8 Fitting Mass Loss Data 
The mass loss data collected for cuboid and cylindrical polymers were used for fitting 
with the linear, quadratic, and cubic polynomials. The collected data during the erosion 
period were used since there are no considerable changes during the induction period to 
be evaluated. Mass loss data were fitted to the functions using Microsoft Excel and the R2 
for each fit was calculated for two of the polymers (Figure 3-13). The results of curve 
fitting for other cuboid and cylindrical polymers are shown in Appendix B-1 and B-2. 
Table 3-3 summarizes the mathematical equations and the R2 values of each fit to the 
mass loss data for a cuboid and a cylindrical polymer. Although polyanhydrides are well 
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known for their near-linear mass loss, the linear equation does not describe the mass loss 
data very well, as also indicated by lower R2. The best fit for both the cylindrical and 
cuboid polymers mass loss data is the cubic equation because of the slightly higher R2 
values in comparison to quadratic functions.  
 
Figure 3-13: Fitting mass loss data for two cylindrical polymers with initial mole ratios of 
PETMP: EGDT = 100:0 and 50:50. The linear, quadratic, and cubic fits and their R2 show that the 
best fit is the cubic function. 
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Table 3-3: Mass loss data fitting. Linear, quadratic, and cubic polynomials were fitted to the 
mass loss data of four polymers with different compositions of monomers in two different shapes. 
 
 
3.2.3 Release Kinetic Models Fitting 
The curve fitting toolbox of MATLAB R2016 was used to fit the mass loss data to the 
above-mentioned equations mentioned in Table 3-1. A model with the highest R2 
(correlation coefficient closest to 1) and the minimum RMSE (equal to highest 
concentrated data around the line of fit) were considered as the best fitted model. The 
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regression coefficient, R2, and the best-fit model parameters are reported. Figure 3-14 
shows the selected models and their corresponding R2 values. According to Table 3-4 that 
summarizes results for cylindrical systems, the best fit was obtained using the 
Hopfenberg and Hixson-Crowell models for the polymer compositions used in our tablet 
fabrication (PETMP: EGDT = 100:0, 75:25). The same study was conducted for the data 
collected for the cuboid polymers. Figure 3-15 shows some of the experimental data and 
their fitted curves. Table 3-5 summarizes the results for the polymer cubes. The Hixson-
Crowell and Weibull models yield the best fit for the cuboid polymeric system mass loss 
data points.  
Based on the best-fitted models, both cylindrical and cubic systems obeyed the Hixson-
Crowell and Hopfenberg models, which describe polymers with erosion mechanisms 
rather than diffusion-controlled systems. This study, mathematically proved that the 
fabricated polymeric systems undergo surface erosion, which has been shown before 
experimentally29. While finding the best fit models, the parameters of each release kinetic 
models were derived and summarized in Table 3-4 and 3-5. Using these parameters, the 
release of the drug through these polymers can be predicted. The results of curve fitting 
to other models can be found in Appendix C1-5 for both cylindrical and cuboid polymers. 
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Figure 3-14: Selected some of the best fitted kinetic models for cylindrical tablets. 
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Table 3-4: Release kinetic models fitting for a cylindrical system. The models with their 
equations, mole ratios of monomers, R2, and derived parameters are shown in this table. 
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Figure 3-15: Selected best fitted kinetic models for cuboid polymers. 
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Table 3-5: Release kinetic models fitting for cuboid polymers. The models with their equations, 
mole ratios of monomers, R2, and derived parameters are shown in this table. 
 
82 
 
3.3 References 
1. Burkersroda, F. v. & Goepferich, A. M. An Approach to Classify Degradable 
Polymers. MRS Proc. 550, 17 (1998). 
2. Tamada, J. A. & Langer, R. Erosion kinetics of hydrolytically degradable 
polymers. Proc. Natl. Acad. Sci. U. S. A. 90, 552–556 (1993). 
3. Göpferich, A. & Tessmar, J. Polyanhydride degradation and erosion. Adv. Drug 
Deliv. Rev. 54, 911–31 (2002). 
4. Burkersroda, F. Von, Schedl, L. & Göpferich, A. Why degradable polymers 
undergo surface erosion or bulk erosion. Biomaterials 23, 4221–4231 (2002). 
5. Poetz, K. L. et al. Photopolymerized cross-linked thiol-ene polyanhydrides: 
Erosion, release, and toxicity studies. Biomacromolecules 15, 2573–2582 (2014). 
6. Kamaly, N., Yameen, B., Wu, J. & Farokhzad, O. C. Degradable controlled-
release polymers and polymeric nanoparticles: Mechanisms of controlling drug 
release. Chemical Reviews (2016). doi:10.1021/acs.chemrev.5b00346 
7. Siepmann, J. & Siepmann, F. Modeling of diffusion controlled drug delivery. 
Journal of Controlled Release (2012). doi:10.1016/j.jconrel.2011.10.006 
8. Fu, Y. & Kao, W. J. Drug release kinetics and transport mechanisms of non-
degradable and degradable polymeric delivery systems. Expert Opin. Drug Deliv. 
(2010). doi:10.1517/17425241003602259 
9. Mathematical models describing drug release from biopolymeric delivery systems. 
Mater. Technol. (2010). doi:10.1179/175355510X12723642365566 
10. Mathematical models of drug release. in Strategies to Modify the Drug Release 
from Pharmaceutical Systems (2015). doi:10.1016/b978-0-08-100092-2.00005-9 
11. Fallahi-Sambaran, M., Salami-Kalajahi, M., Dehghani, E. & Abbasi, F. 
Investigation of different core-shell toward Janus morphologies by variation of 
surfactant and feeding composition: A study on the kinetics of DOX release. 
Colloids Surfaces B Biointerfaces (2018). doi:10.1016/j.colsurfb.2018.06.064 
12. Dash, S., Murthy, P., … L. N.-A. poloniae & 2010,  undefined. Kinetic modeling 
on drug release from controlled drug delivery systems. ncbi.nlm.nih.gov 
13. Mulye, N. V. & Turco, S. J. An examination of assumptions underlying the first-
order kinetic model for release of water-soluble drugs from dicalcium phosphate 
dihydrate matrices. Drug Dev. Ind. Pharm. (1996). 
doi:10.3109/03639049609063223 
14. Higuchi, T. Rate of release of medicaments from ointment bases containing drugs 
in suspension. J. Pharm. Sci. (1961). doi:10.1002/jps.2600501018 
15. Higuchi, T. Mechanism of sustained‐action medication. Theoretical analysis of 
rate of release of solid drugs dispersed in solid matrices. J. Pharm. Sci. (1963). 
doi:10.1002/jps.2600521210 
16. Korsmeyer, R. W., Gurny, R., Doelker, E., Buri, P. & Peppas, N. A. Mechanisms 
83 
 
of solute release from porous hydrophilic polymers. Int. J. Pharm. (1983). 
doi:10.1016/0378-5173(83)90064-9 
17. Kosmidis, K., Argyrakis, P. & Macheras, P. Fractal kinetics in drug release from 
finite fractal matrices. J. Chem. Phys. (2003). doi:10.1063/1.1603731 
18.     Hixson, A. W., & Crowell, J. H. Dependence of reaction velocity upon surface and 
agitation. Industrial & Engineering Chemistry. (1931) 23(8), 923-931. 
19. Katzhendler, I., Hoffman, A., Goldberger, A. & Friedman, M. Modeling of Drug 
Release from Erodible Tablets. J. Pharm. Sci. (1997). doi:10.1021/js9600538 
20. Langenbucher, F. Letters to the Editor: Linearization of dissolution rate curves by 
the Weibull distribution. Journal of Pharmacy and Pharmacology (1972). 
doi:10.1111/j.2042-7158.1972.tb08930.x 
21. Siepmann, J. & Siepmann, F. Mathematical modeling of drug dissolution. Int. J. 
Pharm. 453, 12–24 (2013). 
22. Qiu, S., Wang, K. & Li, M. In vitro dissolution studies of immediate-release and 
extended-release formulations using flow-through cell apparatus 4. Dissolution 
Technol. (2014). doi:10.14227/DT210214P6 
23. Semwal, A., Kakar, S. & Singh, R. Drug release characteristics of dosage forms: a 
review Aphrodisiac potential of Indian Medicinal plants. View project Chitosan 
View project Drug release characteristics of dosage forms: a review. J. Coast. Life 
Med. 2, 332–336 (2014). 
24. Rutherglen, B. G., McBath, R. A., Huang, Y. L. & Shipp, D. A. Polyanhydride 
networks from thiol-ene polymerizations. Macromolecules (2010). 
doi:10.1021/ma102287v 
25. Cullity, B. D. & Weymouth, J. W. Elements of X-Ray Diffraction. Cit. Am. J. 
Phys. 25, 394 (1957). 
26. Poetz, K. L., Mohammed, H. S. & Shipp, D. A. Surface eroding, semicrystalline 
polyanhydrides via thiol-ene ‘click’ photopolymerization. Biomacromolecules 
(2015). doi:10.1021/acs.biomac.5b00280 
27. Kumar, N., Langer, R. S. & Domb, A. J. Polyanhydrides: An overview. Adv. Drug 
Deliv. Rev. 54, 889–910 (2002). 
28. Chickering, D. E., Jacob, J. S. & Mathiowitz, E. Bioadhesive microspheres, II. 
Characterization and evaluation of bioadhesion involving hard, bioerodible 
polymers and soft tissue. React. Polym. 25, 189–206 (1995). 
29. Shipp, D. A., McQuinn, C. W., Rutherglen, B. G. & McBath, R. A. Elastomeric 
and degradable polyanhydride network polymers by step-growth thiol-ene 
photopolymerization. Chem. Commun. (2009). doi:10.1039/b911557a 
30. Shakesheff, K. M. et al. In Situ Atomic Force Microscopy Imaging of Polymer 
Degradation in an Aqueous Environment. Langmuir 10, 4417–4419 (1994). 
31. Zolnik, B. S., Leary, P. E. & Burgess, D. J. Elevated temperature accelerated 
release testing of PLGA microspheres. J. Control. Release 112, 293–300 (2006). 
84 
 
32. Aso, Y., Yoshioka, S., Li Wan Po, A. & Terao, T. Effect of temperature on 
mechanisms of drug release and matrix degradation of poly(d,l-lactide) 
microspheres. J. Control. Release 31, 33–39 (1994). 
33. Ho, K.-L. G., Pometto III, A. L. & Hinz, P. N. (No Title). J. Polym. Environ. 7, 
83–92 (1999). 
34. Akbari, H., D’Emanuele, A. & Attwood, D. Effect of geometry on the erosion 
characteristics of polyanhydride matrices. Int. J. Pharm. (1998). 
doi:10.1016/S0378-5173(97)00298-6 
35. Strickley, R. G. Pediatric Oral Formulations: An Updated Review of 
Commercially Available Pediatric Oral Formulations Since 2007. Journal of 
Pharmaceutical Sciences 108, 1335–1365 (2019). 
36. Goyanes, A., Robles Martinez, P., Buanz, A., Basit, A. W. & Gaisford, S. Effect of 
geometry on drug release from 3D printed tablets. Int. J. Pharm. 494, 657–663 
(2015). 
37. Martinez, P. R., Goyanes, A., Basit, A. W. & Gaisford, S. Influence of Geometry 
on the Drug Release Profiles of Stereolithographic (SLA) 3D-Printed Tablets. 
AAPS PharmSciTech 19, 3355–3361 (2018). 
38. Reynolds, T. D., Mitchell, S. A. & Balwinski, K. M. Investigation of the effect of 
tablet surface area/volume on drug release from hydroxypropylmethylcellulose 
controlled-release matrix tablets. Drug Dev. Ind. Pharm. 28, 457–66 (2002). 
39. Makino, K., Ohshima, H. & Kondo, T. Mechanism of hydrolytic degradation of 
poly(l-lactide) microcapsules: Effects of ph, ionic strength and buffer 
concentration. J. Microencapsul. 3, 203–212 (1986). 
40. Göpferich, A. Mechanisms of polymer degradation and erosion. Biomaterials 17, 
103–114 (1996). 
41. Khutoryanskiy, V. V. Supramolecular materials: Longer and safer gastric 
residence. Nature Materials (2015). doi:10.1038/nmat4432 
42. Shieh, L., J. Tamada, I. Chen, J. Pang, A. Domb, and R. Langer. Erosion of a new 
family of biodegradable polyanhydrides. Journal of biomedical materials research 
28, no. 12 (1994): 1465-1475. 
43. Rosen, H. B., Chang, J., Wnek, G. E., Linhardt, R. J. & Langer, R. Bioerodible 
polyanhydrides for controlled drug delivery. Biomaterials (1983). 
doi:10.1016/0142-9612(83)90054-6 
44. Durham, O. Z., Poetz, K. L. & Shipp, D. A. Polyanhydride Nanoparticles: Thiol-
Ene ‘Click’ Polymerizations Provide Functionalized and Cross-Linkable 
Nanoparticles with Tuneable Degradation Times. Aust. J. Chem. 70, 735–742 
(2017). 
 
 
85 
 
Chapter 4  
4 High-throughput Fabrication of Drug-loaded Core-shell 
Tablets for Personalized Medicine 
In this chapter, a high-throughput platform is developed for fabricating drug-loaded 
tablets. The tablets, achieved using a novel tablet design, have adjustable release rates. 
4.1 Materials and Methods 
This section details the materials used in this study and describes the methodology used 
for designing and manufacturing the drug-loaded polymeric tablets with adjustable 
release profiles. 
4.1.1 Materials 
4-Pentenoic anhydride (PNA), 2, 2-(Ethylenedioxy)diethanethiol (3,6-Dioxa-1,8-octane-
dithiol, EGDT), Pentaerythritol tetrakis(3-mercaptopropionate) (PETMP), 1-
Hydroxycyclohexyl phenyl ketone, Trichloro(1H, 1H, 2H, 2H-perfluorooctyl)silane and 
acid orange 10 (orange G) were purchased from Sigma Aldrich Chemical Co. and were 
used as received. SU-8 2050 photoresist was purchased from MicroChem Corporation. 
3D printer acrylate-based resin (Clear 2005T) was purchased from MiiCraft. Both the 
Sylgard 184 Silicone Elastomer pre-polymer and the curing agent were purchased from 
Ellsworth Adhesive Chemical Co., and were used for making PDMS. 3.3 mm poly 
(methylmethacrylate) sheets (PMMA) were purchased from McMaster-Carr. Tyfon 
Microbore tubing (ID 0.079 in) was purchased from Cole-Parmer, Inc. 
4.1.2 Polymer Synthesis Procedure 
1-Hydroxycyclohexyl phenyl ketone (photo-initiator, 0.1wt %) was weighed and placed 
into a 15 ml Falcon tube. Then, PNA was transferred into the tube, followed by the 
mixture of EGDT and PETMP.  The solution was mixed to obtain a homogenous 
mixture. The initial mole ratio of PNA to the total amount of monomers containing thiol 
groups (EGDT and PETMP) was 100:100. In this study, four different initial mole ratios 
of PNA to PETMP and EGDT were prepared and used including PNA: PETMP: EGDT = 
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100:100:0, 100:75:25, 100:50:50, and 100:25:75. The homogenous pre-polymer solution 
was then purged under the inert gas (nitrogen or argon) for 3 minutes and was transferred 
to PDMS molds. PDMS molds with different designs and geometries were fabricated and 
used according to the desired final geometry of each polymer (see section 4.1.3 for 
information on molds fabrication). The pre-polymer solution in molds was exposed to 
UV-light (CL-1000 UVP Cross-linker) equipped with 365 nm UV lamps (intensity=~5 
mW/cm2) for 5 minutes. To study the release profiles of dye-loaded tablets, a model 
compound (acid orange) was added to the pre-polymer solution of some of the tablets. 
Acid orange 10 (1-3wt %) was weighed and added to the purged solution and mixed 
using sonication for 25 minutes. Similar to the pre-polymer without the model compound, 
the dye-loaded solution was transferred to PDMS molds and was synthesized under the 
same UV light for 5 to 15 minutes. The reaction scheme is presented in Appendix A-1. 
4.1.3 Fabrication of 3D Printed Master Molds 
3D printer master molds were used to fabricate the PDMS molds in which the pre-
polymer solutions were polymerized. The master molds were printed by a commercial 
DLP 3D printer (PICO2, ASIGA). Desired 3D models were designed by AutoCAD 
software and were printed layer by layer from a UV-curable resin (Clear 2500T). The 
layer thickness was set to 250 µm, and the irradiation time for each layer was 5s. The 3D 
printed objects were treated using sonication in ethanol for 10 min and washed by 
Deionized (DI) water to remove any uncured polymer. 
4.1.4 Tablet Design 
The tablet has two main parts: the core and the shell (Figure 4-1A). The core is made of a 
surface eroding polymer loaded with a drug (shown in orange in Figure 4-1) while the 
same polymer without any drug is used for the shell (the grey parts in Figure 4-1). The 
core is enclosed by the shell and is placed closer to the top surface compared to the other 
faces. When the thickness of the shell is “large enough” for all sides except the top, the 
release of the drug only from the top surface of the tablet is ensured (Figure 4-1B). This 
design relies on the surface eroding behavior of the polymer which preserves the tablet 
structure and integrity during erosion and ensures that the polymer erodes at a similar rate 
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from all sides. An experiment was conducted that verified the latter (section 4.1.5). 
Therefore, in this design the water first reaches the drug at the top. As the thickness of the 
shell is large enough, the drug will be released completely from the top before the water 
reaches it from the other sides. Accordingly, the release profile of the drug is only 
governed by the variations in the surface area of the drug-loaded core along with its 
height (Figure 4-1C). As an example, in Figure 4.1, the surface area of the tablet core 
from the top is increasing along its height, showing that this tablet is designed for 
obtaining an increasing release profile (Figure 4-1D). 
 
Figure 4-1: Schematic illustrations of core-shell tablet design for an “increasing” release profile. 
The core is shown in orange, and the shell is the grey part. A) 3D view and B) front view showing 
that the core is closest to the top surface. The shell is made of the same polymer, with larger 
thickness than the core’s height on the other sides. C) Release of the drug-containing part when 
the tablet is immersed in PBS. D) The expected release profile of the drug for this tablet design. 
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4.1.5 Tablet Characterization: Height and Diameter Reduction 
Rates 
To ensure that the polymer erodes at similar rates from all sides, the erosion of cylindrical 
thiol-ene polyanhydrides was studied. Four thiol-ene polyanhydride cylinders with initial 
mole ratios of 100:100:0, 100:75:25, 100:50:50, and 100:25:75 were synthesized in 
cylindrical PDMS molds. The PDMS molds were fabricated using 3D printed master 
molds with the diameter and height both equal to 8.7mm. The synthesized polymers 
(cylindrical tablets) were immersed in 10 ml PBS (pH=7.4) in glass vials, before being 
placed on a shaker (VWR micro-plate shaker). The shaker was set up at room 
temperature and the shaking rate of 120 rpm. The diameter and height of the tablets were 
measured frequently (approximately one every hour) during erosion. For each 
measurement, tablets were removed from the solution and their surfaces were slowly 
wiped off using disposable wipers. The dried tablets were then put on a printed coloured 
graph paper, and the photos were taken using a Canon SX201 IS digital camera from four 
different sides of each tablet, before putting the tablet back in PBS. Images from the top 
and bottom of the tablet were used to monitor the diameter reduction, while the two 
images from the sides provided information on variations in the tablet’s height. The NIH 
ImageJ software (version 1.8.0) was used to measure tablet dimensions from photos taken. 
Experiments were repeated three times for each polymer. 
4.1.6 Micro-fabrication of the Tablet Core 
A microfluidic network that was fabricated using the conventional standard photo- and 
soft-lithography techniques1,2 was utilized to create the dye-loaded polymers used as the 
core of the tablets. Steps are shown in Figure 4-2 starting from using a silicon wafer as a 
substrate. The SU-8 photoresist was poured on a four-inch silicon wafer, and a 300 μm-
thick layer of photoresist was spin-coated (Laurell Tech Corp.) on the top surface of the 
silicon substrate. Considering the photo- and soft-lithography procedure for micro-
fabrication, a photo-mask that replicated the final desired shape is used. In the design for 
the core of the tablet, instead of using the shape of a single tablet core for the photo-
mask, a high-throughput pattern of tablet cores was designed using AutoCAD software 
which was then printed as the photo-mask on a high-transparent sheet (Figure 4-2A). The 
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SU-8 photoresist (with the desired thickness spin-coated on the substrate) was covered by 
the photo-mask and was exposed to high-intensity UV-light (AB-M Inc.) for 80 seconds. 
When using a photo-mask, the UV-light only passes through the UV-transparent parts, 
crosslinking only the desired areas on SU-8. Therefore, the SU-8 photoresist polymer 
hardened only at the designed pattern and the other parts remained uncross-linked. Lastly, 
SU-8 developer was used to remove the uncross-linked photoresist from the wafer, 
yielding the final SU-8 mold (Figure 4-2B). 
 
Figure 4-2: Schematic illustrations of the micro-fabrication procedure to create the SU-8 mold. 
A) Coating the SU-8 photoresist on top of the silicon wafer and putting the printed photo-mask 
containing the designed patterns on top of the SU-8-coated silicon substrate. B) Exposure of the 
substrate to the UV light in order to cross-link specific parts and then washing away the uncross-
linked parts using the SU-8 developer. 
Figure 4-3 shows an example of the design for high-throughput manufacturing of the 
tablet core for an increasing release profile. First, the SU-8 master molds were fabricated 
using the above-mentioned steps (Figure 4-3 A, B). To fabricate the microfluidic device, 
the PDMS polymer mixture containing the 1:10 ratio of the base to curing agent was 
thoroughly mixed. To eliminate the trapped air bubbles created in the PDMS sample, the 
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mixture was degassed in a vacuum chamber for 15 minutes. As shown in Figure 4-3C, 
the negative PDMS mold is developed and peeled off from the SU-8 positive mold. To 
facilitate the peel-off process, the SU-8 mold was silanized to make the mold’s 
micrometer-sized channels more hydrophobic. The positive SU-8 mold was silanized 
using (tridecafluoro-1,1,2,2- tetrahydrooctyl) trichloro silane by putting the mold in a 
sealed petri-dish on a hot plate for 2 hours at 65°C. To make the PDMS replica mold, the 
mixture was poured on top of the SU-8 mold and were cured in an oven for 2 hours at 80 
°C. Finally, the cured PDMS was easily peeled off from the SU-8 master mold, yielding 
the high-throughput patterns connected through the microfluidic network (Figure 4-3 C). 
 
Figure 4-3: Micro-fabrication of a high-throughput design to create the tablet core. A) UV-light 
exposure to the SU-8 layer covered with the printed photo-mask containing the high-throughput 
patterns of the tablet core (in this case, the increasing release profile design). B) The positive SU-
8 mold containing the embossed features. C) Pouring the PDMS on top of the SU-8 mold and 
peeling off the final negative PDMS mold once cured in the oven. 
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A platform for using the fabricated PDMS negative molds to make the polymeric tablet 
cores was designed (Figure 4-4). Another PDMS negative mold with a pattern mirrored 
to that of the original was fabricated and placed on top of the original PDMS negative 
mold, making a microfluidic network with 600 µm in thickness for the channels. The top 
PDMS negative mold was punched on two sides with a 2 mm biopsy punch (EMS-Core 
Sampling Tools) to create inlet/outlet ports through which solutions can flow in the 
channels created by the two PDMS negative molds (Figure 4-4). The two PDMS layers 
were sandwiched between two rigid PMMA sheets (3.3 mm thickness). Uniformly 
distributed holes were designed using AutoCAD software and were cut on PMMA sheets 
using the CO2 laser (SUNCOO K40 laser cutter). These holes were designed for using 
screw-nuts through which a uniform force was applied to squeeze two PDMS layers 
together to prevent any leakage of solutions. At the center of the top PMMA sheet, a 
pattern was cut using the laser cutter to allow exposure of the solution in the PDMS 
layers to UV-light (Figure 4-4) for curing the tablet cores. 
  
Figure 4-4: Two PDMS layers sandwiched by two rigid PMMA sheets equipped with holes 
designed to embed screw-nuts for applying uniform forces on PDMS layers. Squeezing two 
PDMS layers using the uniform forces, eliminates the potential leakage of the solutions through 
microfluidic channels. 
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4.1.7 High-throughput Setup for Fabrication of Core-Shell Tablets 
Pre-polymer solutions were prepared as described in the polymer synthesis section. In 
this study, two pre-polymer solutions with initial mole ratios of PNA: PETMP: EGDT = 
100:100:0, and 100:75:25 were prepared. Approximately 5 ml of solutions containing 1 
wt% of acid orange 10 (orange G) model compound were transferred into a vial. The 
solution was continuously injected into the microfluidic network from the inlet port using 
the Tygon Microbore tubing (0.79″ID) (Figure 4-5A). A vacuum pump was connected to 
the outlet, helping draw the solution to fill the champers. After the solution filled the 
chambers completely, the features were exposed to UV-light (UVP Crosslinker, intensity 
= ~5mW/cm2) for 5 minutes.  The screws were then opened and the three connected dye-
loaded tablet cores were peeled off by separating the two PDMS layers.  
The cured micro-fabricated features (the three connected tablet cores) were then placed in 
cylindrical PDMS wells (Figure 4-5B) fabricated using master molds printed by 
commercial DLP 3D printer. The procedures for the fabrication of the 3D printed master 
molds were the same as the steps described in section 4.1.3. The 3D model of the wells 
was designed so that when the high-throughput micro-fabricated cores are placed in the 
wells, each of the cores stay at the center (from the sides, horizontally) and at a pre-
determined distance from the bottom and the top of the well (vertical alignment). 
Particularly, as explained in section 4.1.4, the cores were closest to the top and far 
enough from all other sides of the wells. After placing the dye-loaded cores in the wells, 
the empty spaces around the polymers inside the wells were filled using the same pre-
polymer solution as the core but without any model compound. Another 5 minutes of 
UV-exposure was conducted to cure the newly added polymer solution. Finally, three 
tablets were peeled off from the PDMS wells (Figure 4-5B) and simply were separated 
using a blade by cutting the connecting part. To allow reusing the PDMS molds, the 
channels were washed after peeling off the dye-loaded polymer using the mixture of 
water and ethanol. After washing the channels carefully, they were dried using high-
pressure air for 2 minutes that also ensures cleaning the molds from dirt and possible 
residues. 
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Figure 4-5: Schematic representations for the high-throughput fabrication of the core-shell 
tablet using A) A high-throughput set up to manufacture the tablet cores. Microfluidic channels 
were filled by a dye-containing polymer solution that was injected from a reservoir. The vacuum 
pump helps the solution flow through the network. The first round of the UV-light exposure was 
used to cure the connected features. B) Micro-fabricated features were placed and aligned in 
PDMS wells. Empty spaces were filled with the same polymer without any dye. Using the second 
round of UV-light exposure, the final tablets were fabricated. 
4.1.8 Tablets for Achieving Adjustable Release Profiles 
The ultimate goal of this study is to achieve different release profiles through a novel 
tablet design fabricated by a high-throughput fabrication platform. To meet this goal, 
different tablet geometries were designed using AutoCAD software. Figure 4-6 indicates 
the design of the high-throughput tablet cores which are connected to each other. These 
tablet cores were designed for the increasing (Figure 4-6A), and the constant release 
profiles (Figure 4-6B). The width of the tablet cores design is increasing and uniform 
from the top along their heights in the increasing and constant tablets, respectively. 
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Figure 4-6C shows a different design for the core of tablets with constant release profiles 
that have two, three, or four constant release cores in each connected feature (this design 
will be described in details in the next section). These designs were printed as photo-
masks and went through soft-lithography steps for making the PDMS molds containing 
connected features as a microfluidic network. 
 
Figure 4-6: High-throughput CAD designs for A) Increasing release profile tablet core. B) 
Constant release profile tablet core (one-arm design). C) Constant release profile tablet core (two-
arm, three-arm, and four –arm designs). 
The micro-fabricated cores for the increasing and constant release profiles were placed 
into PDMS wells where the pre-polymer solution without drug was poured and 
polymerized under the UV-light. The three tablets for each geometry were placed in 5 
mL PBS at pH=7.4 separately before being placed on a shaker which was set at 37°C 
with shaking rate of 120 rpm. Almost every hour, 750 µl of each PBS solution was 
withdrawn, transferred into three wells of a 96-well plate (each well contained 250 µl), 
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and analyzed using a micro-plate reader (Asys UVM 340) instrument. The concentration of 
the model compound in a 250 µl sample was calculated using the absorbance measured by a 
micro-plate reader (Asys UVM 340) instrument. The concentrations were calculated using the 
concentration-absorption calibration curve that was obtained by measuring the 
absorbance of different known concentration of acid orange 10 in the wavelength with 
the maximum absorbance of UV light (475 nm) (Appendix D-1). The wavelength in 
which the model compound (orange G) has the highest absorption of UV-light was 
identified by finding the maximum absorbance of acid orange 10 in solutions with known 
concentrations shown in Appendix D-1. For the UV microplate reader device, the 
absorbance-concentration relation was calculated as shown in Equation 4-1 where A is 
the absorbance of the UV light by the model compound and C is the concentration of the 
model compound in the sample. The absorbance is linearly related to the concentration. 
The slope (α in Equation 4-1) was calculated for the micro-plate reader to be 27.13 by 
fitting a linear line to absorbance-concentration data. 
𝐴 = 𝛼 𝐶 (4-1) 
The absorbance of each sample was measured using the UV-plate reader, and the 
concentration of the model compound in the sample was calculated using the Equation4-
1. An equivalent amount of the fresh PBS (750 µl) was added after withdrawing the same 
amount of solution. After collecting the concentration data of the model compound at 
certain time intervals, the fractional release (Equation 4-2) and the release rates 
(Equation4-3) of the model compound from each tablet were calculated. In Equation 4-2, 
𝑀0 is the initial amount of the dye dispersed in the tablet which is known, 𝐶𝑖 is the 
concentration of the model compound calculated for the 𝑖𝑡ℎ sample at time 𝑡, 𝑉𝑡 is the 
total volume of the sample (e.g., 5mL in this study), and 𝑉𝑖 is the withdrawn sample 
volume (250 µl per well or 750 µl per sample), and 𝐹𝑖% is the fractional released 
percentage of the dye. 
𝐹𝑖 % =  
𝐶𝑖 × 𝑉𝑡 +  ∑ 𝐶𝑗𝑉𝑖
𝑖−1
1
𝑀0
× 100 (4-2) 
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In Equation 4-3, 𝑅𝑖 is the release rate of the model compound at time 𝑡 for the 𝑖𝑡ℎ sample, 
and 𝑇𝑖 is the time at which the 𝑖𝑡ℎ sample was withdrawn. 
𝑅𝑖 =
(𝐹𝑖 − 𝐹𝑖−1) × 𝑀0
𝑇𝑖 − 𝑇𝑖−1
 (4-3) 
4.1.9 Modified Tablet Designs to Increase the Loading Capacity 
The tablet designs were modified to improve the capacity of the tablet for containing 
higher quantities of therapeutics. One arm, two-arm, and four-arm designs for the core of 
the tablets were devised to make use of extra spaces in the shell of cylindrical tablets. In 
the modified designs, instead of using only the axial direction for releasing the dye, the 
radial directions were used as well by loading the dye in two-arm and four-arm tablet 
designs. Figure 4-7 A to C shows the schematic illustrations of the one-, two-, and four-
arm tablet designs in front view, respectively. Although in the one-arm design, the core is 
closest to the top of the tablet (same as the tablet designs described so far), in the two and 
four-arm designs, the core is as close to the right, left, and bottom of the tablet as to the 
top side. It means the water could access the dye from one, two, and four sides for the 
tablets shown in Figure 4-7 A, B, and C, respectively.  
As was shown in Figure 4-6C, similar to the increasing and constant designs, the 
modified tablets are designed in a high-throughput connected pattern. The tablet cores 
were printed as photo-masks and were fabricated using the high-throughput micro-
fabrication method previously discussed. Similar to what was described in section 4.1.7, 
tablets’ shells were fabricated with the help of PDMS cylindrical wells. Three separated 
tablets for each design were immersed in PBS solution for the release test using the same 
procedure mentioned above. The concentration of the model compound was calculated 
using the absorbance values measured by the micro-plate reader. The fractional 
percentage model compound released and the release rates for these three modified 
designs were calculated using Equation 4-2 and 4-3 and then compared to each other. 
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Figure 4-7: Schematic representations of modified tablet design to improve the loading 
capacity. Front view of A) one-arm tablet design. B) two-arm tablet design. C) four-arm tablet 
design. 
4.1.10 Automated Tablet Designs 
After determining the tablet design and choosing the suitable polymers for the tablets, the 
tablet geometry is usually designed using computer-aided design (CAD) or drawing 
software. There are several variables that should be considered for designing polymeric 
tablets. Most of these variables are dependent on the physicochemical properties of the 
polymers which affect their degradation or erosion kinetics. Polymeric tablets are 
typically designed by AutoCAD software after solving the complex mathematical 
equations governing the drug release kinetics. Expert tablet designers use powerful tools 
and software to calculate the dimensions and design the geometry of the tablet by 
considering all the essential variables.  
Automation of the tablet design process saves a considerable amount of time and money 
in the manufacturing process of personalized tablets. It also allows physicians to rapidly 
design a tablet-based on the desired release rate, without the need for an expert designer. 
A few commercial software programs were recently introduced that helps non-expert 
individuals design commercially-available tablets in a user-friendly platform. For 
example, in silico tablet formulations can be developed and tested using the formulation-
computer aided design (F-CAD) software platform of CINCAP 3. Researchers have also 
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used TabletCAD (Natoli Engineering Company), which is a simple web-based user 
interface for designing tablets that can be directly linked to the manufacturing process4.  
In the design, using the bio-erodible polymer simplifies the automation of the tablet 
design. This is due to the decreased calculation complexity required for determining the 
drug release profiles from these polymers. In this study, a graphical user interface (GUI) 
was created using the Python programming language for rapid designing of the patient-
specific erodible tablets via a user-friendly platform without the need for expert 
designers. The required dosage (concentration) of the drug during the course of treatment, 
i.e., the desired release profile of the drug, are determined based on the diagnosis of the 
physicians (Figure 4-8A). The thickness of the tablet core (which is 600 µm, in this case) 
and dimensions reduction rates of the polymers, measured in section 4.2.1, were entered 
as inputs. The weight percentage of the drug dispersed in the polymer was also 
determined in the visual indicator. The 2D tablet core was automatically designed using 
the user interface program based on the inputs. (Figure 4-8B). The complete explanation 
of this developed user interface and an example of automated core design for the pulsatile 
release tablet is included in Appendix E-1. 
 
Figure 4-8: Automation of tablet designs. A) The importance of the personalized medicine and 
automated tablets design based on the patient’s physiological condition. "Doctor with Patient 
Cartoon.svg from Wikimedia Commons by Videoplasty.com, CC-BY-SA 4.0". B) The graphical 
user interface was created for designing patient-specific tablets with specific release rates. 
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4.2 Results and Discussion 
This section presents and discusses the results of the tablet characterization, high-
throughput fabrication of the tablet design, adjustable release profiles obtained from 
various tablet designs, and modified designs to improve the loading capacity of the 
proposed controlled-release tablets. 
4.2.1 Tablet Characterization: Height and Diameter Reduction 
Rates 
Several studies have shown that polyanhydrides predominantly undergo surface 
erosion5,6. Researchers have connected the surface erosion mechanism to the linear mass 
loss profile of polyanhydrides that results in a near zero-order drug release from these 
polymers7,8. Most of these studies used polyanhydrides in the form of a slab (a thin layer 
of polymer). Using the new type of polyanhydrides synthesized by thiol-ene 
photopolymerization, a rectangular slab (2× 10 × 10 mm) made of PNA and PETMP 
showed a linear mass loss profile. More complicated mass loss profiles were observed for 
a cube made of the same polymer9. In section 3.2.2.8, the mass loss behavior of cylinders 
and cubes made of the polymers was examined over time. Results showed that the mass 
loss of these polymers closely followed the cubic and quadratic functions rather than a 
linear profile. The non-linearity observed in the mass loss profile of the more complex 
thiol-ene polyanhydride geometries (such as cubes and cylinder), does not contradict the 
surface eroding behavior of the polymer. Surface erosion behavior is defined as the 
quality to preserve the tablet structure during the erosion time. This unchanging structure 
of tablets is attributed to a similar dimension reduction rates in all directions. In this 
section, the diameter and height variations for each tablet were monitored and calculated 
from the photos that were taken at specific time intervals (approximately once every 
hour) after the induction period. The average of the measured diameters and heights from 
triplicate experiments for each tablet were plotted over time. 
Results indicate the linear behavior of the dimension reduction for cylindrical tablets as 
shown in Figure 4-9A, B. As discussed in section 3.2.2.1, an increased ratio of EGDT to 
PETMP in the thiol-ene polyanhydrides network results in higher erosion rates. The rates 
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of the reduction for both diameter and height of all the tablets were calculated by finding 
the slope of the linear curves fitted to the measured data. Table 4-1 summarizes the 
results of the reduction rates for diameters and heights of these four tablets. The 
dimension reduction profiles in Figure 4-8 show that the reduction of diameters and 
heights for each tablet is linear. In addition, similar diameter and height reduction rates 
are observed for tablets made of the same polymers. Having the same reduction rate in 
different dimensions is a very crucial characteristic for a polymer because it increases the 
polymer’s applications in CRSs. The adjustable release rates from the tablet designs rely 
on similar reduction rates in different dimensions. 
The linear behavior of the reduction rates (the calculated correlation coefficients R2 ≈1) 
observed in both dimensions (shown in Figure 4-9 A, C), allowed calculating the 
expected dimension reduction rate of the same polymer for a new cylindrical design. 
Ideally, this expected reduction rate can be calculated by measuring the dimensions of the 
tablet at least at two arbitrary time points during erosion and fitting a linear function to 
dimension vs. time data. The slope of the dimension-time data represents the reduction 
rate. This linear behavior of the reduction rates showed in this study eliminates the need 
for monitoring tablet dimensions during the erosion time. For example, by having the 
initial and final dimensions and the erosion time, the reduction rates can be easily 
calculated and used in the tablet design for releasing the pre-determined patterns of drugs. 
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Figure 4-9: Linear reduction profiles of A) Diameters of four cylindrical tablets. B) Heights of 
four cylindrical tablets. Schematic illustrations of C) horizontal direction of a cylindrical tablet 
monitored to measure the diameter reduction rates and D) vertical direction of a cylindrical tablet 
monitored to measure the height reduction rates. 
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Table 4-1: Diameter and height reduction rates measured for cylindrical tablets. 
 
4.2.2 Micro-fabrication of Tablet Cores 
The designs of tablet cores, previously shown in Figure 4-6, were printed as photo-masks 
and the SU-8 master molds were fabricated through photolithography steps (Figure 4-10 
A). The PDMS molds were successfully fabricated via a standard soft-lithography 
process using the SU-8 master molds. The depth of the chambers on PDMS negative 
molds was measured using a microscope (Nikon 334 Eclipse Ti-E). The measured depths 
ranged from 298 µm to 301 µm for different molds that are very close to the designed 
value (300 µm), showing the successful fabrication of PDMS negative molds.  
The original PDMS layer and the one with the mirrored pattern were put on top of each 
other to create 600 µm cavities between them (Figure 4-10 B). Typically, two PDMS 
layers irreversibly bound to each other or a PDMS layer bonds to a glass slide using a 
standard O2 plasma activation process to make a microfluidic network
10–12. However,  the 
pattern can be destroyed by the formation of an irreversible seal between the PDMS mold 
and a glass slide 13. Besides, in this study, there was a desire to access the features and 
remove the dye-loaded polymer solution once it is cured in the network. Therefore, to 
seal the channels and at the same time prevent the leakage of the fluid, at first, small 
clamps were used to squeeze the two layers together as shown in Figure 4-10 C. 
However, leakage of the polymer solution from the microfluidic channels was observed 
using the clamps. Alternatively, two rigid PMMA sheets were utilized to sandwich the 
PDMS layers. Screws and nuts were used to apply uniform force and to secure the 
alignment. This platform was designed and fabricated for creating the tablet cores. The 
successful injection of the pre-polymer solution containing the model compound via 
inlet/outlet ports is shown in Figure 4-10 D. 
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Figure 4-10: Development of the PDMS microfluidic network for creating the tablet core. A) 
SU-8 master mold fabricated to make PDMS replica molds B) Putting two PDMS layers with the 
mirror patterns on top of each other to create microfluidic cavities with 600 µm depth in between. 
C) Using clamps for squeezing two PDMS layers for the elimination of the potential leakage. D) 
Using two PMMA sheets to apply uniform forces on PDMS layers using uniformly distributed 
screws. 
4.2.3 PDMS Wells for Fabrication of Tablet Shells 
To create the tablet shell, PDMS wells were successfully fabricated using 3D printed 
master molds. Firstly, cubic wells were designed in a way that the distance between every 
two adjacent cubes was the same as the distance between the two adjacent micro-
fabricated tablet cores. The dye-loaded tablet cores were placed at the center of the wells 
at a certain height (as explained in section 4.1.7) using external aligners. Two aligners 
were used to hold the fabricated dye-containing part at the specific XYZ position. Figure 
4-11A shows the printed cubic wells, the PDMS negative molds, and the three cubic 
surface eroding tablets created in the cubic PDMS wells. 
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Figure 4-11B shows an alternative design for the cubic wells’ in AutoCAD in which two 
aligners were added at both ends of the 3D printed object. Two aligners were designed 
with certain heights and a notch on them where the micro-fabricated tablet cores hang to 
ensure the right XYZ position. These two aligners facilitate the correct placement of the 
fabricated dye-containing part in the right location inside the well, without the need for 
external aligners. All the tablet shell designs were changed to cylindrical objects (Figure 
4-11C) since tablets with cubic shapes have sharp corners that are inconvenient to 
swallow when used as oral tablets. The final optimized design was the cylindrical wells 
with two aligners in both sides and two more aligners between every two adjacent wells 
(Figure 4-11D). Aligners between wells were added to prevent the micro-fabricated part 
from bending or collapsing due to the gravity.     
The resolution of the method used for fabrication of the tablet core is of higher 
importance than that of the tablet shell. The geometries of the μm-sized tablet cores 
determine the release profile of the model compound and are also more complex than the 
geometries of the mm-sized PDMS wells that form the tablet shell. However, this design 
benefits from a higher resolution technique for producing PDMS wells (DLP 3D 
printing), that is also capable of printing various geometries with sharp corners or 
curvatures including cubes, cylinders, and spheres which are the common form of tablets 
in the pharmaceutical industry. Higher surface quality of the tablet shells also ensures 
more precise control over the erosion rate of the tablet in the novel design proposed in 
this study. Lithography-based 3D printers (SLA and DLP) can create objects with more 
complex designs at a higher speed and higher resolutions compared to the other 
commercially available 3D printers such as FDM machines. SLA utilizes lasers to cure 
the photo-curable solution point by point, while DLP uses a digital projector to cast and 
cure an entire slice of objects14. In this study, a DLP 3D printer (PICO2, ASIGA) was 
used to fabricate the master molds because of its fast and high-resolution manufacturing 
process compared to the SLA counterparts. The limitation of the lithography-based 3D 
printers is the limited number of the available UV-curable resins. Clear 2500T resin was 
used after evaluating its thermal stability in an oven for 2 hours at 80 °C, which is the 
same thermal condition for curing the PDMS on top of the printed master molds. 
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Figure 4-11: Development of PDMS wells fabricated using the 3D printed master molds. A) 
Cubic 3D printed master mold, PDMS cubic wells created using the master mold, and three 
surface eroding polymers in a cubic shape fabricated using the PDMS mold. B) The new version 
of the cubic well design with two aligners in both ends of the mold and the printed master mold. 
C) Modified cylindrical wells design and the printed object. D) Final optimized cylindrical wells 
design with four aligners to hold the tablet core. 
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4.2.4 High-throughput Fabrication of Core-Shell Tablets 
The cores and shells of the tablets were fabricated using the developed platform 
described in section 4.1.74.1.6 for high-throughput manufacturing of the tablets. As an 
example, the results of the high-throughput fabrication of the increasing release profile 
tablets are shown in this section. Figure 4-12A shows the final device, developed for 
fabricating the dye-loaded cores of the tablets. Figure 4-12 shows three tablet cores for 
the increasing release profile that were fabricated and peeled off from the μm-sized 
PDMS mold. The cross-linked dye-loaded features were set in place using the notch 
aligners embedded in the PDMS wells that were created using the 3D printed master 
molds (Figure 4-12B). Empty spaces in the wells were filled by the same surface eroding 
polymer without the model compound. All three wells were then exposed to the UV-
light, and the final connected tablets were peeled off from the PDMS wells as shown in 
Figure 4-12C. These connected tablets were simply separated to obtain three individual 
tablets for the increasing release profile (Figure 4-12D). 
 
Figure 4-12: High-throughput fabrication of the increasing release profile core-shell tablets. A) 
High-throughput platform to create the micrometer-sized tablet cores. B) Locating the cured 
micro-fabricated tablet cores on PDMS wells to create the tablets’ shells. C) Three connected 
core-shell tablets peeled off from the PDMS wells. D) Three separated increasing release profile 
tablets. 
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4.2.5 Tablets with Adjustable Release Profiles 
The proposed tablet design in this study was tested at first for the constant release profile. 
The constant release profile tablets were designed such that the surface area of the tablet 
core from the top along its height was constant (Figure 4-13A). Figure 4-13B shows the 
constant release profile core-shell tablet in PBS solution after the first half of the core is 
eroded. The concentration of the model compound in the sample was measured 
approximately once every hour and the fractional cumulative release of the model 
compound was calculated and plotted over time (Figure 4-13C). Results show the linear 
fractional release of the model compound. On the top left on the graph in Figure 4-13C, 
the release rate of the model compound is plotted. The release rate is not changing over 
time which agrees with the pre-determined constant release profile intended by the tablet 
design. 
To demonstrate the versatility of the tablet design, a different core-shell tablet was 
designed and fabricated. The core was fabricated for a decreasing and then increasing 
release profile of the model compound, as shown in Figure 4-14A. The surface area of 
the tablet core from the top along its height is decreasing and then increasing. Figure 4-
14C shows the fabricated core-shell tablet for decreasing-increasing release profile 
(Figure 4-14B) in PBS solution after the first half of the erosion period. The fractional 
cumulative release of the model compound was calculated and plotted (Figure 4-14D) 
over time. The fractional release of the model compound shows two distinct sections, one 
during the erosion of the decreasing part and the other happens during the erosion of the 
increasing part. The data for these two parts were fitted to two quadratic models using 
MATLAB MathWorks software. On the top left on the graph in Figure 4-14 D, the 
release rates of the model compound were plotted which show a decreasing and then an 
increasing release rate over time. 
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Release rates calculated for the constant and the decreasing-increasing release profile 
core-shell tablets showed the feasibility of tuning the release pattern of the model 
compound from the polymer using the proposed core-shell tablet design. The release 
profile patterns were only dependent on the tablet’s core geometry, particularly the 
variations in its surface area from the top along its height, as well as the location of the 
tablet core inside the shell. The linear reduction rates of the erodible tablets’ dimensions 
Figure 4-13: Constant release profile of a core-shell tablet. A) The schematic representative of 
the tablet core with the constant surface area from the top along its height and the position of the 
tablet core are shown in the tablet front view. B) The fabricated constant release profile core-shell 
tablet in PBS while it is eroding. C) The linear fractional drug release after the induction period 
and the constant drug release rate on the top left side. 
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(calculated in section 4.2.1), make it possible to estimate the release profiles of the drugs 
from the tablets. Compared to other studies conducted on obtaining desired release 
profiles from polymeric tablets15–17, the presented method is more straightforward and 
does not require the complex modeling and/or solving of the complicated equations for 
designing tablets with adjustable release profiles. 
 
Figure 4-14: The decreasing-increasing release profile core-shell tablet. A) The schematic 
representative of the tablet core with decreasing and then increasing surface area from the top 
along its height and the location of the tablet core shown in the front view. B) The fabricated 
decreasing-increasing tablet core C) The fabricated decreasing-increasing release profile core-
shell tablet in PBS while it is eroding. D) The fractional model compound release after the 
induction period and the decreasing-increasing release rates on the top left side. 
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4.2.6 Modified Tablet designs towards Increasing the Loading 
Capacity 
The drug-loading capacity of a polymeric delivery system is the total amount of the drug 
that can be loaded in the system and depends on the polymer, drug, fabrication method, 
and the design of the DDS. As discussed before in section 3.2.2.6, in the tablet design, a 
higher intensity UV-light source was required to cross-link the polymers containing 
higher amounts of the model compound (or any other therapeutics). The high-intensity 
UV-light transfers very high energy that may damage to therapeutics loaded in the 
polymer. By modifying the tablet design and utilizing the extra space in the shell of the 
tablet, higher amounts of the model compound can be loaded into the tablets without 
increasing the total volumes of the tablets.   
The height and the diameter reduction rates for polymers used in this study were 
measured before in section 4.2.1 and results showed the similarity of the reduction rates. 
One-arm, two-arm, and four-arm core-shell tablets were fabricated ( 
Figure 4-15A) using the high-throughput platform. The same weight percentage of the 
model compound was added to these three tablet designs so that the total initial amount 
of the dye loaded in the two-arm and four-arm tablets was two and four times higher than 
the one-arm loaded dye, respectively. The cumulative release of the model compound 
from all three tablets was calculated and the mean values from triplicate experiments 
were plotted as shown in Figure 4-15B. Linear curves were fitted to data and slopes were 
calculated, showing the constant release rates as expected (considering the tablet core 
designs).  
Figure 4-15C, D, and E show the tablets fabricated for constant release profiles while 
they are eroding in PBS. The cumulative release of the model compound over time was 
linear for all three fabricated tablets which acted as another indicator of obtaining a 
constant release profile. Slopes of the linear lines were calculated to show the constant 
release rates reported in  
Figure 4-15B. The release rate of the four-arm tablet was almost four times higher than 
the release rate of the one-arm tablet and the slope of the linear cumulative release of the 
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two-arm tablet showed an almost twofold increase when compared to the one-arm tablet. 
These findings also imply that using the four-arm design, it was possible to load (and 
release) the same amount of model compound at almost four-times lower weight 
percentage compared to the one-arm tablet. Consequently, the intensity of the UV-light 
source required for curing the photocrosslinkable polymeric tablet cores will be reduced 
which lowers the chances of damages to loaded drugs. Moreover, the results of this 
experiment showed that more amount of the drug could be released using other sides of 
the tablet as well as the top side, while preserving the desired release profile. 
Researchers have studied the elevation of the loading capacity of controlled DDSs by 
changing the polymer compositions18. Various fabrication techniques such as hot-melt 
extrusion (HME) and injection molding (IM) were also used to increase the loading 
capacity of the polymeric tablets19–21. In this study, using the modified tablet designs 
which utilize more dimensions of the tablet for releasing the therapeutics, the loading 
capacity of the designed tablets was increased by approximately four times. 
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Figure 4-15: Modified core-shell tablet designs to increase the loading capacity of the delivery 
system. A) Three core-shell tablets, fabricated for constant release profile with one-arm, two-arm, 
and four-arm cores from left to right, respectively. B) The cumulative amount of the model 
compound release after the induction period and linear fitted curve to the one-arm (the blue line), 
two-arm (the green line), and four-arm (the red line) release data. The slopes are showing the 
constant release rates in mg/hr. The core-shell tablets fabricated for constant release profiles 
while eroding in PBS for C) one-arm, D) two-arm, E) and four-arm tablets. 
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Chapter 5  
5 Conclusions and Future Directions 
In this thesis, the mass loss profiles of the thiol-ene polyanhydrides were 
comprehensively studied, before utilizing them in the fabrication of tablets that were 
designed to obtain adjustable release profiles. A high-throughput platform for 
manufacturing the tablets is also presented. This chapter summarizes and highlights the 
relevance of the thesis and guides future works. 
5.1 Conclusions 
5.1.1 Chapter 3 
The photocrosslinkable thiol-ene polyanhydrides were successfully synthesized as was 
indicated by the close agreement between the FTIR spectra of the polymers (Appendix 
A-2) with the previously reported FTIR results for the same polymers. The glass 
transition temperature values of the synthesized polymers using DSC were in agreement 
with the values measured by DMA for the same polymers1.  
The impact of the polymer composition on the polymer mass loss profiles (both the 
induction and the erosion period) was studied by changing the initial mole ratios of the 
cross-linkers (PETMP to EGDT). Although changing the polymer compositions did not 
affect the induction period, an increased initial mole ratio of EGDT to PETMP resulted in 
a shorter total erosion time (Figure 3-3). The reasons behind the changes in the erosion 
times were investigated. The water contact angles of polymers were decreased for higher 
EGDT to PETMP ratios. The lower values of the water contact angle indicate the lower 
relative hydrophobicity of polymers, owing to their less cross-link density1 (Table 3-2). 
Results of the PXRD, together with the results of the DSC experiments, illustrated the 
lack of the crystallinity in the polymer structures (Figure 3-2 and Appendix A-4). The 
amorphous domains of the polymers ensured that the crystallinity cannot be the reason 
for the change in the erosion rate. Therefore, the difference in cross-link density, and 
hence the hydrophobicity of polymers with different EGDT to PETMP ratios was found 
to be the primary reason for the change in the erosion rates. 
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The effect of the tablet geometry on mass loss profiles of the polyanhydrides was 
examined by first comparing the mass loss profiles of small cylindrical tablets with the 
larger ones made of same polymers. Similar induction periods and erosion patterns were 
observed for the two tablet geometries (Figure 3-4), indicating that the thiol-ene 
polyanhydrides maintain their surface erosion behavior even at very small dimensions 
(e.g., 3mm which is in the range of our tablet cores’ size) similar to other types of 
polyanhydrides2. Results show the potential of this type of polyanhydrides to be used in 
small-size controlled DDSs, in particular for manufacturing mini-tablets for pediatric 
patients. In another set of experiments, the impact of the surface area, volume, and SA/V 
ratio on the erosion behavior of the tablets were examined (Figure 3-6 to 3-8). While the 
induction period was not affected by these parameters, the mass loss percentage for a 
polymer with a higher surface area and/or a lower volume was shown to be faster. 
Polymers with the same SA/V ratios showed similar mass loss percentage rates despite 
their dissimilar volumes and surface areas. The important role of the SA/V ratio in the 
degradation behavior of tablets made of other biodegradable polymers has been shown 
before3,4. 
The impact of parameters such as the temperature, pH, and shaking rate of the PBS on the 
mass loss profile of thiol-ene polyanhydrides was studied. A decrease in the induction 
period (from 10 hours to 5 hours) was observed in the mass loss profile of the polymers 
when the temperature was increased (25°C to 37°C). The erosion was considerably faster 
at higher temperatures (Figure 3 4). The findings are in agreement with other studies 
showing that the degradation of biodegradable polymers is accelerated at elevated 
temperatures5–7. The induction periods and mass-loss rates were similar for polymers in 
different pH, except for the one at pH=7.89, which showed a shorter induction period and 
a faster mass loss rate (Figure 3 9). The increased mass loss rate of the polymer in the 
alkaline solution is in agreement with results from other studies that showed an 
acceleration in degradation of biodegradable polymers in more alkaline environments8,9. 
The induction period and mass loss rate of polymers stayed similar at three shaking rates 
(0, 60, 120 rpm), with a slightly slower erosion rate observed at a static condition (Figure 
3-10). These findings indicated the non-significant effect of the shaking rate on mass loss 
profile of this type of polyanhydrides which is similar to the behavior observed for 
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another type of polyanhydride with the slightly slower erosion rate in the solution with a 
lower shaking rate10.  Mostly, adding hydrophilic compounds (such as the neutral form 
of the lidocaine) to the polymers might decrease the cross-link density, which leads to a 
faster mass loss. Although the dispersion of various amount of lidocaine (1, 2, and 3wt 
%) in other cross-linked thiol-ene polyanhydrides caused slightly faster mass loss11, 
dispersion of the 1 wt% model compound (acid orange 10) in the present polyanhydrides 
did not make a difference in the mass-loss rates of the tablets (Figure 3-11).    
The feasibility of eliminating the undesirable induction period (lag time) of thiol-ene 
polyanhydrides was studied by pre eroding the polymers in PBS. After pre-erosion, i.e. 
removing the tablets from PBS after the duration of the induction period and keeping 
them in vacuum for 10 hours, when placed back in PBS polymers started eroding with a 
similar mass loss rate without any second induction period (Figure 3-12). Elimination of 
the lag time for a different polyanhydride (PCPM) by pre-erosion process has been 
reported12. The successful elimination of the pre-erosion can be attributed to a decrease in 
the hydrophobicity of the polymer surface caused by the hydrolysis that occurs when the 
tablet is in contact with PBS in the pre-erosion period. Overall, temperature was the only 
parameter that could affect the induction period substantially. The mass-loss rate, 
however, was influenced by most of the parameters studied, including the polymer 
composition and geometry as well as the temperature, pH, and shaking rate of the PBS 
solution during the in vitro experiments. 
Chapter 3 also documented data on the mass loss behavior of the cylindrical and cuboid 
thiol-ene polyanhydrides by fitting their experimental mass loss data to linear, quadratic, 
and cubic polynomials. Even though a linear mass loss profile is commonly reported for 
surface eroding polymers2,13, the mass loss data of the present polymers more closely 
followed the cubic and quadratic functions (Figure 3-13 and Table 3-3). The geometry of 
the tablets is the reason behind this non-linear behavior of the mass loss data. Polymers in 
the form of a slab show a linear mass loss while cubes or cylinders made of the same 
polymer show more complicated patterns. The release kinetic models fitting was also 
conducted to further investigate the mass loss profiles of the polymers. With the highest 
R2 and the lowest RMSE, the Hopfenberg and Hixson-Crowell models best fitted to the 
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cylindrical and cubic systems’ mass loss data (Table 3-4 and 3-5). These best-fitted 
models describe the erosion mechanism of the systems rather than the diffusion 
mechanisms that govern the other kinetic models used for data fitting. 
5.1.2 Chapter 4 
The surface erosion behavior of the photocrosslinkable polyanhydride was studied in 
chapter 3 and results demonstrated that it is an appropriate candidate to be used for 
fabricating drug-loaded tablets. Chapter 4 presented a novel core-shell tablet design in 
which the core is made of a surface eroding polymer loaded with a drug, while the same 
polymer without any drug was used for the shell (Figure 4-1). The position of the tablet 
core inside the shell is such that the core is closest to the top, and far enough from the 
other sides, ensuring that the release of the drug happens only from the top surface of the 
tablet. Accordingly, the release profile of the drug is only governed by the variations in 
the surface area of the drug-loaded core along its height. This design relies on the surface 
eroding behavior of the polymer to preserve the tablet structure and integrity during the 
erosion, as well as the similarity of the erosion rate at all sides of the tablet.  
The tablet design requires only one type of surface eroding polymer in contrast to other 
designs that utilized multiple polymers in tablet fabrication. For example, PLA has been 
used in the form of layers or containers for achieving delayed, sequential, pulsatile, 
release profiles as well as designs with adjustable release profiles14–18. Using multiple 
polymers for manufacturing the tablets increases the time and complexity of the 
fabrication process. Besides, the interactions between different polymers used in a DDS 
can change their properties, and hence their erosion behavior. If not accounted for, this 
may result in erroneous estimations of the release profile of drug from the DDS. 
Therefore, in addition to characterizing the erosion behavior of each of the polymers 
separately before manufacturing the tablet, studies should be conducted on characterizing 
the erosion behavior of each of the polymers from the multi-polymer DDS after it is 
manufactured. In addition, some polymers used in the multi-polymer DDSs have slow 
degradation rates, e.g. PLA that is usually utilized for fabricating containers can take 
several months to degrade19,20. The tablet design developed in this thesis overcomes the 
aforementioned issues by utilizing only one surface eroding polymer. 
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The design for achieving adjustable release rates relies on the similarity of the dimension 
reduction rate of different sides of the tablet, i.e. the independence of the dimension 
reduction rate from the orientation of the tablet. The diameter and height reduction rates 
of cylindrical tablets made of thiol-ene polyanhydrides were obtained from mass loss 
experiments and were found to be linear and very close to each other (Figure 4-9). The 
linearity of the dimension reduction rates allows for estimating the dimension reduction 
rate of a new cylindrical design made from the same polymer, without the need for 
monitoring the tablet dimensions during the entire erosion time. 
High-throughput manufacturing is currently a challenge for producing advanced 
controlled DDSs with adjustable release rates. Most of the studies reported the fabrication 
of a single tablet in each experiment18,21–23, reducing the chances of their practical use in 
clinical settings.  Manufacturing each tablet can take a considerable amount of time, and 
the reproducibility level is low. In this study, a platform for high-throughput 
manufacturing of the core-shell tablets was developed to provide adjustable release 
profiles.  
Tablet cores were fabricated using a microfluidic network consisting of two PDMS layers 
manufactured using conventional soft-lithography techniques. To prevent the leakage of 
the pre-polymer solution from the microfluidic network, two rigid PMMA sheets were 
used to sandwich the PDMS layers and to apply a uniform force through a screw/nut 
configuration. The successful injection of the pre-polymer solution via the inlet/outlet 
ports was achieved (Figure 4-10). To create the tablet shell, PDMS wells were 
successfully fabricated using 3D printed master molds. Aligners were designed to ensure 
the right positioning of the micro-fabricated tablet cores in the shell (Figure 4-11).  High-
resolution tablet shells were fabricated by using DLP 3D printing for producing PDMS 
wells. DLP was chosen because it can create objects with more complex designs at a 
higher speed and higher resolutions compared to the other commercially available 3D 
printers such as FDM machines which are previously used for manufacturing tablets with 
adjustable release profiles 18,21–23.  
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Results of the release rates measurements of the tablets designed for constant and the 
decreasing-increasing release profiles showed the feasibility of achieving tunable patterns 
of release using the proposed core-shell tablet design (Figure 4-13 and 4-14). Compared 
to other studies 26–28,  the presented method provides a more straightforward translation of 
the desired release profiles to the tablet design, owing to the linearity of the surface 
erosion rate observed in these experiments, along with the core-shell tablet design. Unlike 
other studies 26–28, complex modeling and/or solving of the complicated equations for 
designing tablets with adjustable release profiles was not required. 
By modifying the tablet design and utilizing the extra space in the shell polymer, higher 
amounts of the model compound was loaded into the tablets without increasing the total 
volumes of the tablets ( 
Figure 4-15). The modified design reduces the chances of the UV-induced damage to 
therapeutics loaded in the tablet. One arm, two-arm, and four-arm designs for the core of 
the tablets were devised by using the radial directions for erosion. The two- and four-arm 
tablets preserved the estimated release pattern. The release rate of the four-arm tablet was 
almost four times higher than the release rate of the one-arm tablet and the slope of the 
linear cumulative release of the two-arm tablet showed an almost twofold increase when 
compared to the one-arm tablet. These findings demonstrated that using the four-arm 
design, it is possible to load (and release) the same amount of the model compound at 
approximately four-times lower weight percentage compared to the one-arm tablet. This, 
in turn, decreases the required UV-light energy for cross-linking the tablet cores and 
hence reducing the chances of the damage to the loaded drugs. Other groups have studied 
elevation of the loading capacity of controlled DDSs by changing the polymer 
compositions29. Various fabrication techniques such as HME and IM were also used to 
increase the loading capacity of the polymeric tablets30–32. In this study, using the 
modified tablet designs, the loading capacity of the tablets was increased by 
approximately four times, in a straightforward fashion. 
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5.2 Future Directions 
To further advance this study, the mass loss measurements can be conducted in PBS 
solutions with changing pHs over time33 to mimic the conditions that a solid oral dosage 
form would experience through the GI tract. In this regard, additional mass loss 
experiments that are conducted in more physiologically relevant environments can help 
provide more accurate predictions of the in vitro and ultimately in vivo erosion behavior 
of these polymers. The release profile studies also need to be conducted for the tablet 
loaded with an actual drug instead of a model compound. 
To reduce the tablet manufacturing time, automation of some steps involved in the 
fabrication of the tablets is recommended. A graphical user interface was developed that 
automatically designs the tablets based on the information provided on the desired release 
pattern (Appendix E-1). Although a pulsatile release profile was shown as a proof of 
concept, other desired release profiles can be input to this user-friendly platform that 
outputs the corresponding tablet design. The output of this program can then be utilized 
for high-throughput fabrication of the tablets with the desired release profiles.  
It is noteworthy that the simultaneous fabrication of three tablets (with either constant or 
decreasing-increasing release profiles) was presented to demonstrate the potential of the 
proposed method for large-scale production. Testing a design that includes a higher 
number of simultaneously fabricated tablets is important to further validate the feasibility 
of the proposed method for mass production. In addition, the design for achieving 
adjustable release profiles should be used and tested for achieving other clinically 
relevant and in-demand release profiles. Lastly, to improve the efficiency of the presented 
delivery system and to further increase the drug loading capacity, other sides of the tablet 
shell can also be utilized for drug release.  A new modified design, together with a 
modified fabrication technique is required to realize this goal. 
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Appendices  
Appendix A: Polymer prepration and characterization. 
 
Appendix A-1: Thiol-Ene polymerization process for synthesizing: A) a linear network made of 
PNA and EGDT. Reproduced from Ref 1 with permission. B) A cross-linked network made of 
thiol-ene reaction of PNA and PETMP and the following degradation via hydrolysis. One or both 
of these networks exist in the final polymer structure used in this study. Reproduced from Ref 2 
with permission. 
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Appendix A-2: ATR-FTIR spectra of A) PNA: PETMP = 1:1 shows the dual peaks of 
anhydrides and the absence of thiol and vinyl functional groups’ peaks similar to Ref 3. B) The 
same peaks for other synthesized polyanhydrides with different initial mole ratios of monomers. 
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Appendix A-3: TGA traces for four polyanhydrides to check their decomposition temperatures 
before doing the DSC experiments. Initial mole ratios of monomers used in samples were PNA: 
PETMP: EGDT= A) 100:100:0. B) 100:75:25. C) 100:50:50. D) and 100:25:75. The 
decomposition temperatures were seen at 329 °C, 328 °C, 324 °C, and 317 °C respectively. 
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Appendix A-4: DSC of four different polymers with initial mole ratios of PNA: PETMP: 
EGDT equal to: A) 100:100:0. B) 100:75:25. C) 100:50:50. D) 100:25:75.Tg were specified from 
the second cycle of heat/cool steps and -25.1°C, -36.6°C, -48.9°C, and -55.8°C respectively. 
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Appendix B: Mass loss data fitting. 
 
Appendix B-1: Fitting mass loss data for cylindrical polymers. The linear, quadratic, and cubic 
fitting curves and the R2 is written in graphs. 
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Appendix B-2: Fitting mass loss data for cuboid polymers. The linear, quadratic, and cubic 
fitting curves and the R2 is written in graphs. 
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Appendix C: Release kinetic models fitting. 
 
Appendix C-1: Fitting mass loss data to the zero-order kinetic model for cylindrical and cuboid 
polymers. 
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Appendix C-2: Fitting mass loss data to the First-order kinetic model for cylindrical and cuboid 
polymers. 
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Appendix C-3: Fitting mass loss data to the Higuchi kinetic model for cylindrical and cuboid 
polymers. 
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Appendix C-4: Fitting mass loss data to the Korsmeyer-Peppas kinetic model for cylindrical 
and cuboid polymers. 
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Appendix C-5: Fitting mass loss data to the Hixson-Crowell kinetic model for cylindrical and 
cuboid polymers. 
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Appendix D: Model compound (Orange G) absorbance-concentration calibration curve. 
 
Appendix D-1: Calculation of the model compound (orange G) concentration. A) Finding the 
wavelength that has the maximum absorbance intensity for OG solutions with known 
concentrations. B) Concentration-absorbance calibration curve for OG at 475nm (maximum 
absorbance) for the micro-plate reader. 
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Appendix E: Automated Tablet design 
The use of bio-erodible polymers simplifies the automation of the tablet design. This is 
due to the decreased calculation complexity required for determining the drug release 
profiles from these polymers. In this study, a graphical user interface (GUI) was created 
using the Python programming language for automatically designing the patient-specific 
erodible tablets via a user-friendly platform without the need for an expert designer. The 
required dosage (concentration) of the drug during the course of treatment, i.e., the 
desired release profile of drugs, is determined based on the diagnosis of the physicians 
(Appendix E-1A). The thickness of the tablet core (which is 600 µm, in this case) and 
reduction rates of the polymers which were measured in section 4.2.1 were entered as 
inputs. The weight percentage of the drug dispersed in the polymer was also determined 
in the visual indicator (Appendix E-1B). The 2D design of the tablet core is automatically 
generated based on the desired release profile that was input to the user interface 
program. (Appendix E-1D). 
For instance, we assume a pulsatile release profile with three peaks over the treatment 
time is requested by the user (the physician). In the tablet design, the drug release profile 
is only dependent on the surface area of the tablet core from the top surface along its 
height. Accordingly, the code calculates the height of the tablet core based on the user-
defined inputs such as the total release time, and the polymer- and design-specific 
variables (e.g. the linear reduction rates of polymers and the amount of drug can be 
dispersed in the polymer). After plotting the 2D tablet core design, the cumulative drug 
release is calculated and plotted (Figure 4-9C). Finally, the 3D tablet designs are created 
in the code by adding the third dimension to the 2D pattern. This thickness is an input to 
the program (Appendix E-1E). 
The 2D tablet core design provided by the user interface program is transferred to the 
AutoCAD software and is attached to the previously designed connected network 
(Appendix E-1F, G). The automation process for designing the tablet core was 
successfully conducted for a pulsatile release profile. The inputs required in this GUI can 
either be obtained from the previously conducted experiments or from the results of a 
138 
 
modeling study. This automation process eliminates the need for manual calculation and 
design for each patient. 
 
Appendix E-1: Automation of the tablet designs. A) Importance of the personalized medicine 
and automated designing tablets based on the patient’s physiological conditions. "Doctor with 
Patient Cartoon.svg from Wikimedia Commons by Videoplasty.com, CC-BY-SA 4.0". B) The 
graphical user interface for designing the patient-specific tablets with specific release rates. C) 
Cumulative drug release calculated by the program. D) The 2D tablet core designed using the 
GUI. E) 3D tablet designed using the GUI. F) Transferred 2D tablet core designs to AutoCAD. 
G) Attachment of the tablet core designs to the connecting network to create the high-throughput 
tablet core designs. 
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